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Asthma 
' 'Asthma is a disease characterized by an 
increased responsiveness of the trachea and 
bronchi to various stimuli and manifested by a 
widespread narrowing of the airways that 
changes in severity either spontaneously or in 
response to therapy." 1 The airway narrowing is 
the end result of some combination of bronchial 
muscle contraction , tissue inflammation , mu-
cosa! edema, and luminal occlusion by cellular 
debris and thickened secretions. During the last 
decade, basic and applied research has shed 
light on the physiology of the above changes 
and has led to breakthroughs in therapy and the 
more rational use of older and newer therapeu-
tic agents, both separately and together. 
Anatomy 
The nasal passages, the oropharynx, and 
the large , and some smaller, bronchi are exten-
sively provided with a variety of receptors which 
respond to temperature and irritating stimuli of 
many types. The sensory signals emanating 
from these receptors and others are transported 
to the central nervous system by the vagus 
nerve . The motor innervation of the bronchi is 
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via the vagus (cholinergic) and sympathetic 
trunks (adrenergic} , both of which affect bron-
chomotor tone and secretions. 
The epithelium of the intrathoracic airways 
is covered with a "mucociliary blanket" which 
facilitates the removal of particulate material ; 
mucus is secreted by glandular epithelial cells . 
Ciliated epithelium constantly moves the mucus 
layer from peripheral to central airways, where 
cough and expectoration eliminate the trapped 
particles from the respiratory tract. 
The multiple branching airways of the 
lung , as far distal as the respiratory bronchiole, 
are surrounded by bands of smooth muscle. 
Proportionately greater amounts of muscle are 
present in small bronchioles relative to large 
and medium bronchi , and constriction of this 
musculature can virtually occlude the airway. 
Physiology 
For any given flow rate, airways resistance 
is dependent on the cross-sectional area 
through which the gas is flowing, that is , the 
larger the cross-sectional area the less the resis-
tance and vice versa. Bronchial smooth muscle 
contraction can markedly increase resistance 
and this can be augmented by compromise of 
the airway 's lumen by secretions, cells, and 
other factors . Stimulation of the vagus nerve in-
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duces bronchial smooth muscle contraction and 
increases mucus secretion; sympathetic nerve 
stimulation has a minimal opposite effect. 
The relative "tone" of bronchial smooth 
muscle, that is, the balance between muscle 
contraction and relaxation, is controlled by the 
intracellular ratio of the cyclic nucleotides. High 
levels of cyclic adenosine monophosphate 
(cAMP), induce relaxation, and conversely, in-
creased levels of cyclic guanosine mono-
phosphate (cGMP), induce contraction . Beta 
agonists (isoproterenol, ephedrine, terbutaline, 
among other drugs) appear to increase levels of 
cAMP by stimulation of the enzyme adenylcy-
clase; corticosteroids may work in this fashion 
as well. Methylxanthines, such as theophylline, 
appear to prevent the breakdown of cAMP by 
the enzyme phosphodiesterase and thus in-
crease intracellular cAMP levels. Vagal stimula-
tion in turn stimulates cAMP production, caus-
ing bronchoconstriction. 2 
Pathophysiology 
A large population of mast cells contain-
ing a variety of preformed "mediators" of hy-
persensitivity such as histamine are normally 
found in the pulmonary interstitium; these cells 
can synthesize from precursors other mediators 
such as a slow-reacting substance of ananphy-
laxis (SRS-A). Both of these substances are 
powerful bronchoconstrictors and may increase 
cell membrane permeability, leading to mucosa! 
edema. Additionally, these mediators increase 
bronchial receptor sensitivity thus enhancing 
neurogenic-induced bronchoconstriction. Other 
mediators can cause inflammatory changes in 
bronchi and attract and activate phagocytic 
cells . 
In extrinsic (allergic) asthma, mast cells 
are sensitized by the attachment of antigen-spe-
cific lgE to their surface. If an appropriate anti-
gen, such as pollen, fixes to the lgE, the various 
mediators are released and/ or synthesized. 3 
The rate of release/synthesis of mediators is 
governed by the cAMP /cGMP ratio in the mast 
I 
cell, and is thus subject to pharmacologic ma-
nipulation as has been discussed. 
In other types of asthma (adult onset, in-
trinsic, aspirin-induced, and other forms) immu-
nologic mechanisms do not play a dominant 
role. Some suggested mechanisms causing the 
airway hyperreactivity in these types of asthma 
are: 
B-adrenergic blockade: A decreased re-
sponse to beta agonist drugs has been noted 
in many asthmatics. It is possible that either 
congenital defects in adenylcyclase production 
or recurrent infections could induce this block-
ade. 
Cholinergic dominance: This hypothesis 
presupposes that the vagus nerve in the asth-
matic is easily stimulated via the irritant recep-
tors, leading to an enhanced bronchoconstric-
tive response (the ''twitchy vagus ' ' theory). 
Cortical (emotional) components may act via 
this pathway. Whether the vagus hyperreactivity 
is a primary or secondary defect is in question. 
Histamine, for example, increases irritant-recep-
tor sensitivity and indirectly plays a role in va-
gally mediated bronchoconstriction . 
Adrenergic amine deficiency: This hypoth-
esis presupposes that in response to broncho-
constrictive stimuli, the adrenal medulla should 
release additional epinephrine to partially mod-
ify this response (epinephrine acting as a beta 
agonist). In the asthmatic, this response is im-
paired . 
Smooth muscle abnormalities: Asthmatics 
are known to have hypertrophied bronchial 
musculature. Whether or not the muscle is also 
innately more reactive is undecided . 
Alpha-adrenergic hyperresponsiveness: 
Some asthmatics have been shown to have an 
exaggerated response to phenylephrine (a pure 
alpha agonist) in organs other than the lung. It is 
thus hypothesized that naturally occurring alpha 
agonists (which increase mast cell and bron-
chial musculature intracellular cGMP) can in-
duce bronchoconstriction . 
Much is still to be learned about asthma. 
Apparently, in all individuals, many factors play 
a role in the pathogenesis of the disease, some 
factors being dominant and others seeming less 
significant. It is the clinician's responsibility to 
determine in his patient which factors pre-
dominate and to tailor the treatment to these 
findings. 
Chronic Obstructive Pulmonary Disease 
(COPD} 
Emphysema and bronchitis constitute the 
major disease entities which fall under the head-
ing of Chronic Obstructive Pulmonary Disease 
(COPD). Although emphysema and bronchitis 
will, for discussion purposes, be considered 
separately, they occur concomitantly in most 
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patients with COPD. Only a small percentage of 
patients will have ''pure ' ' emphysema or 
"pure" bronchitis. 
"Class.ic" Findings in Far-Advanced Em-
physema and Bronchitis 
Emphysema is defined as destruction of 
terminal alveolar capillary units with enlarge-
ment of the remaining air spaces. Etiologically, 
it is causally related to cigarette smoking and 
certain genetic disorders such as alpha 1 anti-
trypsin deficiency. In addition , there is some evi-
dence that recurrent childhood pulmonary in-
fections predispose smokers to emphysema. 
The typical patient with far-advanced em-
physema is 45 to 50 years of age and com-
plains of dyspnea on mild exertion . Unless an 
associated bronchitis is present, cough and 
sputum production do not occur. Physical ex-
amination reveals a thin, cachectic patient with 
an increased respiratory rate , using his or her 
accessory muscles of respiration, an increase in 
anteroposterior chest diameter, a tympanitic 
chest percussion note , and decreased breath 
sounds. Laboratory results are unremarkable 
and the chest radiograph shows a vertical, 
small heart with clear , hyperinflated lung fields; 
· the EKG shows low voltage . Pulmonary function 
tests are consistent with hyperinflation, de-
creased flow rates and diffusing capacity and 
airway collapse . Mild hypoxemia (Pa02 > 55 
torr) and normocapnea (PaC02 < 45 torr) are 
common findings . Because of the labored 
breathing and lack of cyanosis this type of pa-
tient has been termed the " pink puffer." As 
lung destruction is the basic problem, most 
therapeutic interventions are nonrewarding, but 
teaching the patient to purse-lip breathe may 
lessen the dyspnea and decrease the respira-
tory rate. 1 
Chronic bronchitis is defined as an in-
crease in sputum production two to three 
months out of the year for two years in a row. 
Patients with this condition usually are cigarette 
smokers and/or have been exposed to indus-
trial or air pollutants. Their chief complaint is a 
cough productive of sputum , often described as 
"a cigarette or morning cough ." The bronchitic 
patient shows no evidence of weight loss , has a 
normal chest AP diameter but may have, on 
auscultation , wheezes, rhonchi , and early in-
spiratory rales . In addition, signs of right ven-
tricu lar failure (jugular venous distention, hepa-
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Fig- Decreases in FEV 1 with age in nonsmokers, non-
susceptible smokers and susceptible smokers. This graph 
depicts fall in FEV1 in one particular susceptible smoker. 
Other smokers will have different FEV 1 loss rates thus 
reaching the " disability" line at different ages. See text for 
explanation 'i_lnd discussion . 
tomegaly, and peripheral edema) may be 
present. Polycythemia and, in certain cases, ei-
ther sputum or blood eosinophilia may be found 
on routine laboratory analysis. Carbon dioxide 
retention (PaC0 2 > 45 torr) and hypoxemia 
(Pa02 < 55 torr) are found on arterial blood gas 
analysis; pulmonary function tests reveal de-
creased flow rates which may respond to 
bronchodilators. Chest radiography shows an 
enlarged heart (mainly right ventricle) with in-
creased bibasilar lung markings; the EKG may 
show right ventricular hypertrophy. Because of 
the cyanosis and the peripheral edema, these 
patients have been termed "blue bloaters." 
Treatment consists of antibiotics for recurrent 
pulmonary infections, diuretics and digitalis for 
the right heart failure and supplemental oxygen 
for the hypoxemia. 
Which Patients are at Risk of Developing 
Symptomatic COPD? 
The patient with far-advanced COPD re-
sponds poorly to treatment and the average life 
expectancy after severe symptoms ensue is 
3 Y2 to 5 years. 2 It would be advantageous to 
predict which patients who smoke may develop 
far-advanced disease as it is now known that · 
90% to 95% of all smokers are either not sus-
ceptible or minimally susceptible to the effect of 
cigarette smoke; that is, life-long smoking does 
not lead to symptomatic lung disease as de-
scribed above. Most cigarette smokers have 
normal or near normal FEV 1s compared to age-
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matched nonsmoking controls (Line A, Figure). 3 
A small percentage of patients, however, may 
be susceptible to cigarette smoke and if FEV 1 s 
are performed yearly (after age 40), there will 
be a marked decline in the FEV, per year (Line 
B, Figure) compared to normal values (Line A, 
Figure). If these patients continue to smoke, 
they will become symptomatic and disabled at a 
relatively early age; if they stop smoking, the 
FEV, decline will slow (Line C, Figure), but im-
paired pulmonary functions may be demon-
strable, although the patient may be asympto-
matic. If smoking is stopped late in the course 
of the disease (that is, by the time disability oc-
curs), although the FEV1 decline will improve, 
death will ensue in a relatively short period of 
time (Line D, Figure). Therefore, FEV 1s should 
be performed yearly in all cigarette smokers > 
40 years of age. If a marked loss of FEV1 oc-
curs (> 60 to 70cc/sec/yr), an aggressive ap-
proach to cessation of smoking should be insti-
tuted. 
The Figure is modified by permission from the British 
Medical Journal 1(1 : 1645-1648, 1977). 
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Diseases Which Mimic Asthma and Chronic 
Obstructive Pulmonary Disease (COPD) 
GEORGE W. BURKE, Ill, M.D. 
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Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
The American Thoracic Society defines 
asthma as a disease characterized by increased 
responsiveness of the trachea and bronchi to 
various stimuli and manifested by widespread 
narrowing of the airways that changes in sever-
ity either spontaneously or as a result of ther-
apy. 1 In this context asthma is a physiologic di-
agnosis. It is most often recognized when a 
patient complains of episodic wheezing and 
dyspnea and most often confirmed by the dem-
onstration of variable airways obstruction on 
spirometric testing . 
Chronic bronchitis, on the other hand, is 
characterized by excessive mucous secretion in 
the bronchial tree and manifested by chronic or 
recurrent productive cough present on most 
days for a minimum of three months in the year 
and for not less than two successive years. 1 
Therefore, chronic bronchitis is a clinical diag-
nosis of exclusion, dependent upon a con-
stellation of nonspecific symptoms. Emphy-
sema is an alteration of the lung characterized 
by an abnormal enlargement of air spaces distal 
to the terminal bronchioles with destructive 
changes of the alveolar wall. 1 Confirmation of 
emphysema may be difficult because it is de-
pendent upon lung anatomic findings or the ap-
pearance of obvious bullae on chest roentgeno-
gram; moreover, it is recognized that chronic 
bronchitis and emphysema occur together and 
it may be difficult to predict which of these con-
ditions is the dominant cause of chronic airways 
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W. Burke, 111 , Box 637, Medical College of Virginia, Rich-
mond, VA 23298. 
obstruction in an individual patient. To circum-
vent this difficulty, clinicians have preferred to · 
use the term "chronic obstructive lung disease" 
(COPD) with the understanding that this term 
implies the probable coexistence of both bron-
chitis and emphysema. 
From a practical standpoint , clinicians 
customarily respond to specific '' signals'' for 
the detection of asthma or COPD. Common ex-
amples are a patient 's complaint of wheezing 
episodes, the demonstration of airways obstruc-
tion on spirometric testing , or detection of hy-
percapnia on arterial blood gas analysis. Appro-
priate interpretation of these signals requires not 
only knowledge of the definitions of asthma and 
COPD but also an awareness that there are nu-
merous other diseases which can produce 
these signals and thereby mimic asthma or 
COPD. 
The purpose of this report is to review and 
demonstrate, by case reviews, diagnostic pit-
falls in the approach to patients with diseases 
which mimic asthma or COPD. 
CASE 1. A 20-year-old white female college stu-
dent complained of an exacerbation of coughing, 
mucopurulent sputum, and wheezing in April 
1 9 7 4. She had experienced numerous identical 
episodes since 1967 and had noted gradually 
progressive exertional dyspnea. In 1 96 7, be-
cause of wheezing, a physician had diagnosed 
"asthma" and prescribed a compound contain-
ing theophylline and glyceryl guaiacolate. She 
was referred to an allergist who detected cutane-
ous hypersensitivity to multiple allergens and ad-
ministered desensitization injections. Despite 
these interventions, her symptoms continued. 
Past medical history revealed undiagnosed 
chronic diahrrea during childhood. A physical ex-
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Fig 1-Posteroanterior chest roentgenogram of case 1 
showing faint reticular densities in all lung fields and in-
creased subcardiac air. 
amination revealed a well-developed and well-
nourished female. There were inspiratory crack-
les in the upper lung fields, diffusely diminished 
vesicular sounds, and mild digital clubbing. The 
chest roentgenogram (Fig 1 ) showed scattered 
coarse reticular densities and subcardiac air . 
Physiologic studies revea led a forced vital capac-
ity of 3 05 liters {predicted value, 3.54 liters), a 
one-second forced expiratory volume of 1 .68 lit-
ers/sec (predicted value , 2.44 liters/sec), and a 
maximum mid-expiratory flow of 0 .96 liters/sec 
(predicted value, 2.98 liters/sec). Sweat chloride 
values exceeded 60mEq/liter on three occa-
sions, thus conf irming the diagnosis of cyst ic fi-
brosis. 
Comments: There is evidence to suggest that 
differences in genetic factors or penetrance 
may influence the course of cystic fibrosis. 2 
Some patients may not develop the typical 
wasted and chronically-ill appearance and be-
cause of this , cystic fibrosis may be easily over-
looked in adolescents or young adults. Futher-
more , over 20% of cystic fibrosis patients may 
remain unrecognized when they reach the age 
of seventeen. 2 Case 1 is an example of this. 
Misdiagnosis resulted in inappropriate and ex-
pensive attempts to provide protection from pre-
sumed pulmonary allergens. Earlier institution of 
correct treatment , consisting of aggressive 
chest physiotherapy and prompt attention to 
specific airway bacterial pathogens , may have 
improved her long-term prognosis . Because 
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cystic fibrosis is the most common cause of 
chronic airways obstruct ion in young adults, 2 it 
represents an important simulator of asthma 
and COPD. 
CASE 2 A 58-year-old female nurse complained 
of progressive wheezing and dyspnea in Decem-
ber, 1 978 . She denied smoking cigarettes, pre-
vious atopy, allerg ic rhiniti s, or asthma and had 
experienced excellent hea lth until June, 1978, 
when she developed episodic "tightness" in her 
chest. This worsened in November, 1978. caus-
ing her to seek medica l attention . Asthma was 
diagnosed and she was given a bronchod ilator 
wh ich temporaril y relieved her symptoms In De-
cember she was hospitalized with severe wheez-
ing and fever. Her past history revealed that she 
had converted to a positive tuberculin test in 
1 9 77 . She had refused to take prophylactic 
ison iazid. A physical examination revealed an 
elevated temperature (1 02 F), tachypnea. use of 
accessory muscles of inspiration, and expiratory 
prolongation of her breath sounds; bilateral dif-
fuse expiratory wheezing was present. The total 
leukocyte count was 16,1 00 cells/ cu mm with 
78% mature neutrophils, 7% band forms , 6% 
lymphocytes, 3% monocytes, and 6% eosino-
ph ils. The absolute eosinophi l count was 5056 
cells/ cu mm. A chest roentgenogram (Fig 2) re-
vealed a " ground glass" infiltrate in the left upper 
lobe. Serologic tests for antibody titers to Myco-
plasma pneumoniae, 0 fever, psittacosis, and a 
variety of vira l agents known to infect the respira-
tory tract were low. Mycobacterium tuberculosis 
was not present on sputum smears or cul tures . 
Arter ial P02 was 54 torr , PC02 32 torr, pH 7.47 
units. After five days of intravenous aminophylline 
her wheezing cleared. Physiologic stud ies re-
vealed a forced vital capacity of 2. 1 7 liters (pre-
Fig 2-Posteroanterior chest roentgenogram of case 2 
showing ill-def ined "ground-glass" infiltrate (arrow) in left 
upper lung fie ld. 
dieted value, 2. 43 liters) , and one-second forced 
expiratory volume of 1 .55 liters/sec (predicted 
value 1 .78 liters/sec). The left upper lobe had 
cleared completely on roentgenogram but was 
replaced by a similar infiltrate in the left mid-lung 
field . Because of these migratory infiltrates asso-
ciated with eosinophilia , Loffler syndrome was 
suspected. Twenty days after admission her 
chest roentgenogram was normal. Physiologic 
studies revealed a forced vital capacity of 2.27 
liters, a one-second forced expiratory volume of 
1.78 liters/sec; arterial P0 2 was 78 torr, PC0 2 
36 torr , pH 7 .41 units. 
Comments: Loffler pneumonia is the mildest 
disorder in a group frequently described as 
"pulmonary infiltrates with eosinophilia " or 
" PIE syndromes." The spectrum of PIE syn-
dromes also includes more debilitating dis-
orders such as chronic eosinophilic pneumonia 
(CEP) or potentially fatal disorders such as poly-
arteritis nodosa.3 Although the etiology and 
pathogenesis of Loffler pneumonia are un-
known , recent detailed pathologic descriptions 
of a single case have shown striking similarities 
to CEP.4 Therefore , distinction between the two 
may have to be made on clinical grounds . 
Loffler syndrome is a self-limited form produc-
ing mild illness , whereas CEP is prolonged and 
may result in severe restrictive impairment, oc-
casional obstructive impairment and large venti-
lation-perfusion imbalances. 3 CEP will resolve 
rapidly with corticosteroid therapy, but relapses 
are common . Loffler pneumonia rarely requires 
corticosteroid therapy . The PIE syndromes may 
be associated with obstruction , wheezing , and 
peripheral eosinophilia , 3 thereby simulating 
asthma as occurred in case 2 . 
CASE 3. In February 1975, on the eve of a skiing 
trip , a 59-year-old male sorting machine me-
chanic developed chills and fever. These were 
followed by malaise and dyspnea. Seven days 
later a dry cough developed . Two weeks follow-
ing the onset of the illness, he was hospitalized 
because of persistent symptoms and an abnor-
mal chest roentgenogram showing coarse, bi-
basilar linear infiltrates. After an unrevealing, non-
invasive work-up , he underwent a right lower lobe 
open biopsy, which was interpreted as showing 
nonspecific inflammatory changes and fibrosis. 
The acute illness apparently resolved. During his 
convalescence, physiologic studies revealed 
moderately severe obstruct ion. He was told that 
he had COPD related to his long-term smoking 
habi t. However, he had smoked cigarettes only 
occasionally and had been able to play tennis 
and ski prior to his illness in February. Since then 
he was dyspneic on exertion and unable to per-
form sports activities. In October, 1976, he 
sought another opinion. A physical examination 
revealed a few scattered posterior wheezes and 
moist ra les with a well-healed righ t thoracotomy 
scar. Chest roentgenogram showed postsurgical 
blunting of the right costophrenic angle but was 
otherwise normal. The physiologic studies (Table 
I) continued to show moderately severe obstruc-
tion , obstructive air trapping, and severe reduc-
tion in diffusing capacity. Histopatholog ic sec-
tions of his previous biopsy were obtained and a 
Van Giesson stain was performed (Fig 3). This re-
vealed numerous remnants of bronchial wall elas-
tin , unrecognized on earlier hematoxylin and eo-
sin staining, which indicated severe bronchiolitis 
obliterans. 
Comments: Bronchiolitis with bronchiolitis oblit-
erans is a well-recognized sequela of acute viral 
infections in infants and children . Among chil-
dren less than 2 years old, respiratory syncytial 
virus accounts for most cases. 5 Because of their 
severe and potentially fatal obstructive compli-
cations, adenovirus types 3, 7 and 21 are an-
other important, although much less frequent , 
cause of bronchiolitis in this age group. 5 On the 
other hand, acute viral bronchiolitis is rarely 
diagnosed in adults . The occasionally recog-
nized case of bronchiolitis obliterans can usually 
be attributed to inhalation of a toxic substance, 
with resultant chemical injury, or to a syndrome 
of rapidly progressive airway obstruction which 
is sometimes seen in rheumatoid arthritis . 6 How-
ever, as a diagnosis by exclusion, viral bron-
chiolitis obliterans seemed likely in case 3. The 
patient denied toxic inhalation and had no 
chemical or serological evidence of rheumatoid 
arthritis . His prodromal symptoms were sugges-
tive of a viral infection. His subsequent clinical 
course further supported this . Although the 
pathogenesis and pathologic lesion in his illness 
TABLE 1 
Physiologic Studies in a 59-Year-Old Male with Bronchiolitis Obliterans 
Vital capacity, liters 
FEV 1 , liters/sec 
Total lung capacity, liters 
Residual volume, liters 
Diffusing capacity, ml / min / torr 
PRE-DRUG POST-BRONCHODILA TOR 
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Fig 3-Histopathologic section of lung biopsy from case 3 showing remnants of bronchiolar wall elastin enmeshed in fibrous 
tissue. The findings are diagnostic of bronchiolitis obliterans (Van Giessen stain x 1 00). 
were quite different from those of COPD related 
to chronic cigarette smoking , his long-term 
prognosis and hope for benefit from pharmacol-
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VOLUME-LITERS 
Fig 4-Flow-volume curve in case 4 showing flattening of 
both inspiratory (lower curve) and expiratory (upper curve) 
loops. The dotted line is a superimposed curve from the 
same patient whi le breathing 80% helium. 
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history of bronchiolitis obliterans in adults is not 
well known . 
CASE 4 . A 12-year-old white male was treated for 
asthma for six years because of wheezing and 
dyspnea. On a routine visit , inspiratory stridor 
was detected. Spirometry showed mild obstruc-
tion (one-second forced expiratory volume 70% 
of predicted). Because of his stridor, a flow-vol-
ume curve was performed to screen for upper air-
way obstruction. Both the inspiratory and ex-
piratory limbs of this curve were flattened 
indicating nonvariable upper airway obstruction 
(Fig 4). A contrast tracheogram revealed an area 
of extreme tracheal narrowing extending from the 
level of the thyroid carti lage to the carina (Fig 5) 
An anomalous right upper lobe bronchus com-
municated with the trachea at the level of the tho-
racic outlet The finding of anomalous bronchial 
drainage in conjunction with the tracheal stenosis 
suggested that all findings were of congenital ori-
gin . . 
Comments.· Tracheal stenosis is usually associ-
ated with postinflammatory scarring because of 
pressure necrosis from indwelling endotracheal 
or tracheostomy tubes. Its occurrence as a con-
genital abnormality in a youth long suspected 
of having allergi c asthma underscores the 
importance of correctly timing abnormal breath 
sounds. Earlier failure to recognize an in-
spiratory component to this patient's ''wheez-
ing" misled the clinicians caring for him. Pro-
longed, and perhaps unnecessary, bronocho-
dilator therapy exposed the patient to expensive 
and potentially toxic medications. The extent of 
the abnormality precluded surgical correction. 
However, after a correct diagnosis was made, 
close attention to clearance of secretions and 
recognition of a permanently limited exertional 
tolerance helped the patient and his family to 
cope with his condition. 
CASE 5. A 36-year-old black male complained of 
exertional dyspnea and massive swelling bf his 
lower extremities in March, 1979. These symp-
toms were oi 12 months' duration and had prog-
ressed to the extent that he was short of breath 
with minimal exercise such as dressing himself. 
He noted frequent nocturia, intermittent ortho-
pnea, and was hypersomnolent during the day. A 
physical examination revealed massive obesity. 
His height was 5 feet, 9 inches; his weight was 
344 pounds. The thyroid gland was not palpable 
and there were no changes ih hair texture or 
quality of his voice. The chest was clear to aus-
cultatiofil . Head sounds were faint with an S4 gal-
lop. Pitting dependent edema to the level of the 
umbilicus was present. Serum urea nitrogen, glu-
cose, and electrolytes were normal as were the 
urinalysis and total leukocyte count. Hemoglobin 
was 1 9. 7 gm%. An electrocardiogram showed 
right axis deviation . Serum free thyroxine was 
normal. A chest roentgenogram revealed car-
diomegaly. The arterial P02 was 38 torr, PC02 
was 56 torr, pH 7.36 units. Supplemental oxy-
gen, digoxin, and furosemide were administered. 
Physiologic studies (Table 2) showed mild restric-
tion and no evidence of obstruction. During 
sleep, the patient was observed io snore loudly 
between apheic spells. This phenomenon was 
documented by simultaneous sleep recordings of 
el!3ctroencephologram ' electrocardiogram' intra-
esophageal pressure (an estimate of intrapleural 
pressure), and air flow at the mouth (Fig 6). While 
in stage II non-rapid-eye movement sleep, he 
demonstrated numerous prolonged apneic spells 
during which he continued to have phasic in-
spiratory efforts, as manifested by persistent 
swings in intrapleural (intraesophageal) pressure. 
This confirmed the diagnosis of obstructive sleep 
apnea. 
Comments: Disordered control of breathing dur-
ing sleep may produce prolonged nocturnal 
hypoxemia and hypercapnia. These; in turn, 
may cause nocturnal pulmonary hypertension 
and gradual '' resetting ' ' of the central chem~ 
oreceptor response to C02 . Eventually, chronic 
hypercapnia and cor pulmonale will occur. Al-
though the precise sequence leading to chronic 
cor pulmonale and hypercapnia are unknown, 
at least three distinct pathophysiologic mecha-
nisms may produce a ventilatory sleep disorder. 
The first , and most common, occurs in patients 
with COPD in whom exaggerated deterioration 
in arterial oxygenation and C02 retention may 
accompany the normal decrease in alveolar 
ventilation during sleep. The second occurs in 
patients with congenital or acquired defects in 
brain stem chemoreceptor or respiratory in-
tegrative functions. They develop apneic spells 
during sleep because respiratory drive from the 
cortex normally ceases, but the brain stem con-
trol mechanisms are unable to maintain normal 
ventilation . 8 The third results from intermittent 
upper airway obstruction, which leads to alveo-
lar hypoventilation interrupted by loud snoring 
spells. Patients with anatomic defects of the up-
per airway, such as mandibular malformations 
or tonsinar hypertrophy, are predisposed to this 
condition . 8 However, the majority of patients 
with obstructive sleep apnea have no recogniz-
able anatomic defect, and the precise mecha-
nism for their intermittent upper airway obstruc-
tion remains unknown.8 They tend to be obese. 
Because their sleep pattern is interrupted by fre-
quent hypoxic spells with arousal, they tend to 
be hypersomnolent during the day. By the time 
they seek medical attention , they ar~ :usually ex-
periencing cardiorespiratory failure. It is appar-,. 
ent that these patients have the cardinal fea-
tures of what was formerly called the 
" Pickwickian syndrome." Case 5 is an ex-
ample of this phenomenon. Often these patients 
are diagnosed as having COPD because they 
have chronic C02 retention and are assumed to 
have chronic diffuse airway obstruction. Mis-
diagnosis of such patients may result in grave 
therapeutic errors. The prognosis for untreated 
obstructive sleep apnea is poor, but the condi-
TABLE 2 
Physiologic Studies in a 36-Year-Old Male with Obstructive Sleep Apnea 
Vital capacity, liters 
FEV;, liters/ sec 
FEV,/vital capacity,% 
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Fig 5-Tracheogram from case 4 showing long segment of 
narrowed trachea well outlined by contrast material. Right 
upper lobe bronchus branches from trachea above the ca-
rina indicating congenital anomalous bronchial tree with tra-
cheal stenosis. 
tion may be alleviated by the performance of a 
tracheostomy to allow for a patent airway during 
sleep. 
In addition to the examples discussed in 
this report , there are other lung disorders which 
may cause obstructive airways disease or C02 
retention (Table 3), either as an occasional 
complication or as a dominating feature. 
Kyphoscoliosis can produce chronic C02 re-
tention and cor pulmonale. However, the mech-
anisms initiating this are obscure because re-
striction, rather than obstruction , is the 
predominant mechanical abnormality. 9 Ad-
vanced tuberculosis may also cause chronic 
C02 retention. Again, the precise mechanism is 
ill-defined although inflammatory bronchial stric-
ture with subsequent obstruction may play a 
role. 9 Because both of these diseases are easily 
recognized, confusion with asthma or COPD 
should rarely occur. 
'' Occupational asthma, '' on the other 
hand , may be difficult to distinguish from the 
more common allergic asthma of atopic individ-
uals. In the former , patients experience revers-
ible airways obstruction after exposure to spe-
cific organic volatile compounds or fibers. 
Fig 6-Sleep recording from case 5 showing cont inued inspi ratory attempts (phasic esophageal pressure) during apneic spell 
as indicated by absence of mouth or nasal air flow. Unlabled channels are electroencephalograms. " EOG" is elec-
trooculograni showing absence of rapid-eye-movements during this apneic spell. 
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Although reaginic antibody may be a factor , 
predisposition to the development of occupa-
tional asthma may be unrelated to the previous 
atopic status of affected individuals. 10 A number 
of compounds have been implicated, common 
examples of which are toluene diisocyanate, 
used in the manufacture of polyurethanes, and 
cotton or hemp dusts, encountered in the mill-
ing and carding processes of textile industries. 10 
Noninfectious, granulomatous inflamma-
tory diseases of the lung may produce chronic 
airways obstruction and thereby create diag-
nostic confusion , especially because these 
diseases more commonly produce restrictive 
defects. Histologically, granulomatous bron-
chiolitis is almost invariably seen in allergic al-
veolitis and sarcoidosis. It is not surprising, 
therefore, that as many as 25% of patients with 
these disorders have reduced one-second 
forced expiratory volumes when expressed as a 
ratio of the forced vital capacity. 1 1 · 1 2 On occa-
sion, obstruction is the dominant mechanical 
deficit in these patients and can occur with 
equal frequency in those with or without a 
smoking history. 
Lymphangioleiomyomatosis is an ex-
ceedingly rare disease of women in child-
bearing years in which hyperplastic nodules of 
atypical smooth muscle cause obstruction of 
pulmonary lymphatics, venules, and bron-
chioles. These, in turn , produce episodic chy-
lothorax, hemoptysis, and progressive obstruc-
tive airways disease. 13 In addition, chest 
roentgenograms in this condition show reticular 
markings associated with supernormal radio-
graphic lung volumes. Although this con-
stellation of clinical findings is distinctive, the 
disease is so rare that the diagnosis is often not 
made without open lung biopsy. Unfortunately, 
the prognosis for women with lung involvement 
is poor with most patients dying within ten years 
of the onset of symptoms. 13 
Respiratory compensation for severe 
metabolic alkalosis may result in ''chemically 
justifiable" C02 retention in order to minimize 
elevation in pH. This well-known phenomenon 
is overlooked with surprising frequency by non-
internists who may be less familiar with inter-
preting arterial blood gas data and may auto-
matically attribute C02 retention to ventilatory 
fai lure. Carried to its full extent , such an error in 
logic may produce a corresponding error in 
treatment. Fortunately, most clinicians recog-
TABLE 3 
Conditions Which Mimic Asthma or COPD 
1 . Upper airway obstruction• 
2 . Sleep apnea syndromes • 
3. Cystic fibrosis• 
4. Kyphoscoliosis 
5. Advanced tuberculosis 
6. Pulmonary infiltrates and eosinophilia (PIE)* 
7. Bronchiolitis obliterans (viral, 
toxic inhalation, rheumatoid)• 
8. Industrial asthma 
9. Sarcoidosis 
1 0. Allergic alveolitis 
11. Lymphangioleiomyomatosis 
12. Severe metabolic alkalosis 
• Discussed in comments of case reports 
nize the phenomenon before instituting therapy 
for acute respiratory failure . 
Table 3 represents only a partial list of dis-
eases which may mimic asthma or COPD. As il-
lustrated by the case reports, correct inter-
pretation of wheezing , obstruction, and C02 
retention depends not only on a knowledge of 
their differential diagnosis but also on obtaining 
an accurate history and physical examination. 
Special studies, such as the flow-volume curve 
illustrated in case 4, are merely confirmatory 
data. These special studies are appropriate only 
when clinical and screening laboratory data 
suggest a specific diagnosis. Therefore, the 
availability of such studies in many medical cen-
ters has not diminished the important role of 
basic bedside clinical skills in the diagnosis of 
obstructive lung disorders. 
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Chronic Obstructive Pulmonary Disease: 
Outpatient Management 
JAMES P. BAKER, M.D. 
Professor and Chairman, Department of Medicine, Eastern Virginia School of Medicine, and Director, 
Pulmonary Care Unit, Norfolk General Hospital, Norfolk, Virginia 
Chronic obstructive pulmonary disease 
has become one of the more common prob-
lems which face physicians both in inpatient 
and outpatient settings. The incidence of the 
disease and increase in mortality have been 
documented in a number of studies as have 
other lung diseases, indicating a general rise in 
pulmonary disorders over the past several dec-
ades. 1-3 Two types of disease are classified un-
der the heading of chronic pulmonary disease: 
chronic bronchitis and pulmonary emphysema. 
Chronic bronchitis is defined as a clinical syn-
drome of cough and sputum production for 
three consecutive months over two consecutive 
years, and pulmonary emphysema is defined as 
the histological expansion and destruction of 
the terminal respiratory units, with loss of struc-
tural elements. The etiologies associated with 
these diseases probably are multiple and are 
beyon'd the scope of this discussion; however, 
two of the causal factors are a hereditary pre-
disposition such as is seen in alpha1-antitrypsin 
deficiency and the continued irritation of res-
piratory tissues by various air pollutants includ-
ing tqbacco smoke.4 
The following discussion of a therapeutic 
program for those who suffer from chronic ob-
structive pulmonary disease is directed toward 
the possibility of maintaining a patient in an out-
patient status because of the need to minimize 
health care costs . 1- 5 
The pathogenetic mechanisms of respira-
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tory distress associated with chronic obstructive 
pulmonary disease share several common de-
nominators (Fig 1 ). The primary problem is air-
ways or bronchial obstruction, thus the physi-
cian should attempt to relieve this condition to 
prevent the cascade of effects that may occur 
later in the course of the illness. Obviously, 
bronc·hial irritation and infection lead to bron-
chial edema, spasm and hypersecretion with re-
sulting bronchial obstruction . This can cause a 
number of difficulties the more important of 
which are problems of pulmonary infection and 
atelectasis, ventilation-perfusion disturbances 
with consequent hypoxemia, hypercapnea, and 
ultimately cardiovascular death, primarily from 
arrhythmias. The series of steps that can be 
taken to avoid the natural progression of these 
problems to mortality are outlined in the Table. 
A major concern for patients with chronic 
pulmonary illness is the necessity of being reas-
sured that their physician is taking an active in-
terest in the treatment and follow-up care of 
their case . While there is no total cure for 
people with chronic pulmonary disease, a rea-
sonable lifestyle can be maintained in most 
cases where the physician is ready to present 
an optimistic outlook and offer encouragement 
in those aspects of treatment that require the 
patient's cooperation. Such guidance is an im-
portant therapeutic factor in combating this ill-
ness and provides significant satisfaction to the 
physician for the time and interest expended . 
Patients with chronic pulmonary disease 
must avoid respiratory irritants; first of all they 
must stop smoking . There is ample evidence 
that while people who have pulmonary impair-
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Fig 1-Pathogenesis of respiratory failure in chronic obstructive pulmonary disease. Remediable aspects in capitals. 
ment and stop smoking continue to have an 
FEV1 that is less than predicted for their size 
and age, the rate of decline in lung function is 
significantly slowed . 7 This is one of the more dif-
ficult aspects of treatment to accept and many 
patients deny that not smoking is of value. It is 
important that the physician continue to encour-
age these people not to smoke, and to maintain 
follow-up of those who will not stop. In addition 
to cigarette smoking, patients should avoid 
other known environmental respiratory irritants 
as well as any inhaled allergens if they are 
known and can be documented. One of the 
most important aspects of a therapeutic pro-
gram is to provide these patients with a home 
that is as free from irritants and allergens as 
possible: pets should be kept outdoors; dust 
generators should be removed from the bed-
room, as this is where the patient spends the 
most time; nonallergenic pillows and bedclothes 
should be purchased; and all animal and cotton 
products should be removed from the bedroom 
if possible and only synthetic, nonallergenic fi-
bers used in rugs, upholstered furniture, drap-
eries, and other items. Consideration should be 
given to purchasing an air filter for the bedroom 
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as well as one for the entire home if simpler 
measures are ineffective. 
The atmospheric environment should be 
controlled at between 40% and 60% relative 
humidity. In addition to this, patients with 
chronic pulmonary disease should drink large 
quantities of liquid each day to assist in 
liquefying the great amount of thickened secre-
tions that their lungs produce; a good rule of 
thumb is 1 2 to 1 4 glasses of water daily or an 
adequate amount of water to dilute urine to the 
point that it looks like water. A vaporizer at 
times of increasing respiratory secretions such 
as with an upper respiratory infection may also 
be useful. 
Bronchial drainage measures should be 
practiced using a simple four-position tech-
nique; three of these positions are illustrated in 
Figure 2. 5 The patient lies with hips elevated 
above the shoulders in each position (in addition 
to face-up) for 5 minutes twice daily. If .a family 
member can be taught chest percussion and/ 
or vibration, this can assist in the removal of the 
increased tenacious secretions. The next proce-
dure is to teach the patient pursed-lip breathing 
which requires that the patient exhale through 
pursed lips as though he or she were whistling. 
This will slow respiratory rate and may maintain 
airways in an open position for a longer time 
during exhalation , thus decreasing air-trapping 
and improving ventilation-perfusion relation-
ships. 
Since many severe pulmonary difficulties 
begin with upper respiratory infections, these 
chronically-ill patients should be instructed to 
keep antibiotics such as tetracycline or ampicil-
lin in their home, and to start on these drugs as 
they develop either an upper respiratory infec-
tion or a change in sputum color or quantity 
which suggests an increase in infection. The pa-
tient 's physician should then be called and, de-
pending upon the degree of difficulty the patient 
is having, the physician should have a Gram 
stain and/ or culture done of the patient's spu-
tum. 3 
The regular use of bronchodilators is a 
cornerstone of therapy for chronic pulmonary 
disease. 3 ·5 6 Patients must be encouraged to 
take their' drugs daily even though their condi-
tion is quiescent. The newer anhydrous amino-
phyllin preparations are generally the best avail-
able. The addition of sympathomimetics such 
as terbutaline or metaproterenol is appropriate if 
further bronchodilation is needed. Inhaled 
bronchodilators are also helpful, but they should 
be used infrequently, as these drugs are easily 
overused. Patients taking inhaled drugs must be 
given careful instructions with a demonstration 
of their proper use. The nebulizer is positioned 
just distal to the open mouth and a deep breath, 
followed by complete exhalation, is accom-
plished to time appropriately the introduction of 
the medication at the beginning of the next in-
spiration; at the onset of this inspiration the 
medication is nebulized via the open mouth. 
The patient holds his or her breath for as long 
as possible following a maximal inspiration and 
slowly exhales through pursed lips. This proc-
ess should be repeated two to three times with 
two to three puffs of bronchodilator each time. 
Patients should be taught to monitor their pulse 
rate and rhythm when taking this type of medi-
cation and to discontinue its use if they develop 
any arrhythmia or tachycardia. 
Another classification of drugs considered 
for therapeutic use is the adrenal corticosteroids 
which may be given either in inhaled or oral 
forms with the inhaled form producing fewer 
side affects. The introduction of steroid therapy 
TABLE 
Chronic Obstructive Pulmonary Disease: Outpatient 
Management 
1 . Physician interest and frequent follow-up 
2. Avoidance of respiratory irritants 
3. Maintenance of adequate humidity and hydration 
4. Practice of bronchial drainage measures 
5. Control of infection 
6. Regular use of bronchodilators 
7. Use of oxygen 
8. Use of steroids 
9. Control of heart failure 
1 0. Other drugs 
11 . Active exercise reconditioning 
12. Patient and family education 
should be based upon indication of failure of the 
above-mentioned bronchodilators and antibiotic 
therapy, or evidence of a clear-cut allergic dis-
order shown by either nasal or sputum eosino-
philia or severe irritation by known allergens. 
The goal of steroid therapy should be to use the 
drugs in their inhaled form and if that is impos-
sible to use minimal amounts of the oral drugs 
on alternate days to decrease side effects. 8 
Another drug available for use is cromolyn 
sodium; patients with definite allergic abnormal-
ities or evidence of allergic-oriented disease are 
more likely to respond to this drug. There is no 
place for the use of either sedatives or tranquil-
izers in the treatment of chronic respiratory dis-
Fig 2-Basic positions for bronchial drainage. 
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ease. These patients are generally anxious, agi-
tated, and frustrated because of their illness 
and / or the hypoxemia and / or hypercapnia 
which are associated with the disease. They are 
quite sensitive to most tranquilizers, particularly 
the benzodiazepams (Valium, Librium, among 
others), and these drugs should be avoided. A 
possible drug for use is hydroxozine (Atarax, 
Vistaril) which at least in parenteral form does 
have some bronchodilator effect and may be 
taken as a last resort in small doses (1 0 mg, 
t.i.d.) after all other possibilities have been ex-
hausted. 
Many patients will have observable evi-
dence of right heart failure or cor pulmonale 
which should respond to the therapeutic regi-
men suggested above; if they do not, first, di-
uretics should be tried , and if they are unsu-
cessful , digitalis may be used. Digitalis gener-
ally does not improve right heart failure as much 
as left heart failure, although it does have some 
effect. It is important to avoid drugs which block 
the effectiveness of beta adrenergic stimulation, 
particularly propranolol which is a beta 1 - and 
2-blocker, as they will make the bronchodilators 
less effective. An effective beta 1-blocker drug 
may be available in the not-too-distant future 
which will permit bronchial dilatation while con-
trolling cardiac arrhythmias without producing 
the kind of problem one regularly sees with beta 
1- and 2-blockade. 
Active exercise reconditioning is of great 
importance for patients with chronic pulmonary 
disease. 1- 3 ·5 ·5 They should begin with a regular 
walking program in which goals are set, such as 
walking a number of blocks (or other measured 
distance) daily in a specified period of time, with 
a planned increase in the rate of walking or a 
decrease in the amount of time it takes to cover 
a certain distance. In addition to this, having an 
exercise bicycle for indoor use during inclement 
weather is of extreme importance. Exercise with 
nasal oxygen may increase the exercise toler-
ance of the patient and permit more rapid prog-
ress; its use in the outpatient setting has been 
demonstrated to be of significant value in reduc-
ing pulmonary hypertension and improving the 
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psychological status of chronically hypoxemic 
patients.9 
In conclusion, an educational program in 
which the family as well as the patient is pro-
vided with information concerning the etiology 
of the disease is very important; a similar one 
which explains the pathogenetic mechanisms 
involved in the illness, what the course and 
prognosis are likely to be, as well as the ratio-
nale for all therapeutic measures introduced, is 
also very helpful. This type of approach will as-
sist most patients to improve and function more 
effectively. 
Figure 2 is reprinted with permission from Dr. Irwin 
Kass. 
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Recent Advances in the Management of 
Chronic Airway Obstruction 
JAMES A. L. MATHERS, JR., M.D. 
Assistant Professor of Medicine, and Medical Director, Pulmonary Function Laboratory, Medical 
College of Virginia, Health Sciences Division of VirQinia Commonwealth University, Richmond, Virginia 
Recent advances in our understanding of 
the natural history of chronic airway obstruction 
have identified aspects of this process that may 
enhance the morbidity and mortality of patients 
with a progressive increase in airway resistance. 
These advances have helped us to be more 
specific in the investigation and quantitation of 
the disease in the pulmonary function laboratory 
and to be more precise in our therapeutic man-
agement. Experience has taught us that the 
most useful measurement with which to charac-
terize the degree of disease and its rate of pro-
gression is the forced expired volume in one 
secorid (FEV1). The comprehensive studies of 
Dr. Charles Fletcher in London have demon-
strated that the single most important therapeu-
tic factor is avoidance of all airway irritants. 1 
The application of aggressive bronchial hygiene 
in patients with obstructive airways disease may 
produce an initial improvement in the FEV1 but 
will not in itself alter the rate of decline in pulmo-
nary function . As the degree of airway obstruc-
tion increases, a number of interrelated physio-
logic abnormalities develop including 
hypoxemia, hypercarbia, polycythemia, cor pul-
monale, and eventually, acute or chronic res-
piratory failure. These abnormalities account for 
most of the morbidity in this condition and the 
majority of patients who develop them have a 
high degree of airway obstruction . It is not un-
usual, however, to see patients with a moderate 
degree of airway obstruction who also manifest 
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these problems. The purpose of this paper is: 
( 1 ) to review the relationship between a progres-
sive increase in airway obstruction and the as-
sociated physiologic abnormalities, and (2) to 
discuss the therapeutic interventions that show 
promise of reducing the morbidity from these 
accelerated physiologic abnormalities. 
Hypercarbia and Airway Obstruction 
In order to identify those patients whose 
clinical condition is significantly worse than an-
ticipated from their level of airway disease, we 
need a readily applicable laboratory marker 
such as the elevated arterial carbon dioxide ten-
sion (PaC02 ) . Several years ago, the relation-
ship between airway obstruction characterized 
by the FEV 1 and the PaC02 was investigated. 2 It 
was noted that when the FEV1 was 1500 cc or 
greater, the PaC02 was normal (PaC02 < 44 
mm Hg). When the FEV1 fell below one liter, the 
patient was as likely to have an elevated PaC02 
as he was to have a normal PaC02 , and when 
the FEV1 was 500 cc or less, the PaC02 was al-
most always in excess of 44 mm Hg. Hyper-
carbia has been identified as an adaptive re-
sponse in those patients who must balance the 
increased work of breathing against adequate 
carbon dioxide clearance and, indeed, this may 
be true in patients with severe airways disease. 
Such a state, however, has two major disadvan-
tages; increased arterial hypoxemia ~md promo-
tion of metabolic alkalosis, which contribute to a 
cycle of events that leads to premature meta-
bolic deterioration . We have identified patients 
with moderate obstructive airway disease 
whose hypercarbia, previously attributed to the 
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airway disease, was in fact, related to condi-
tions amenable to medical management. Fur-
thermore, there are patients who have severe 
obstructive airway disease whose hypercarbia 
is made worse by these same factors . These 
conditions include respiratory disturbances dur-
ing sleep, metabolic alkalosis, and respiratory 
muscle weakness. 
Respiratory Alterations During Sleep 
Recent studies using an ear oximeter have 
clearly demonstrated that gas exchange is not 
stable from moment to moment during the day 
and that a single arterial puncture is not satis-
factory to describe an individual's blood gas 
composition, particularly during exercise and 
during sleep. Healthy adults develop periodic 
breathing during light sleep with an overall re-
duction in minute ventilation of one to two liters. 
Rapid eye movement (REM) sleep may include 
apneas of 1 5 to 20 seconds in normal individ-
uals. Accompanying these episodes, there is an 
elevation in PaC02 of 4 to 8 mm Hg and a re-
duction in arterial oxygen tension (Pa02 ) of 3 to 
1 0 mm Hg. In patients with chronic obstructive 
airway disease, similar fluctuations are found 
but with more profound blood gas disturbances 
that are not directly related to the degree of res-
piratory impairment when awake. There are 
three major abnormalities of respiration that 
may occur during sleep. These are (1) hypoven-
tilation, (2) central apnea, and (3) obstructive 
apnea. Patients with chronic airway obstruction 
may suffer from any of these entities; however, 
the two former problems are far more common 
than obstructive apnea. Episodes of hypoventi-
lation causing hypoxemia and hypercapnia are 
usually brief but have been reported to last up to 
one hour. Alterations in chest wall mechanics 
and airway tone during REM sleep may in-
crease these episodes. Normal, brief central ap-
neas may be prolonged by alterations in the 
ventilatory control of the central nervous sys-
tem. An increase in hypoxic drive produces a 
Cheyne-Stokes breathing pattern. Depression 
of either the hypoxic or hypercapnic drives may 
prolong the apneic spells. 
Spells of nocturnal hypoxemia have been 
demonstrated to cause episodic pulmonary ar-
terial hypertension, fluid retention, and poly-
cythemia. It has been suggested that recurrent 
arterial hypoxemia during sleep produces a sus-
tained elevation of the pulmonary arterial pres-
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sure and cor pulmonale. A major factor contrib-
uting to the prolongation of these episodes of 
hypoxemia is the depression of the central ven-
tilatory response to hypercarbia. As the PaC02 
rises, respiratory acidosis develops and re-
peated and prolonged bouts of acidosis stimu-
late a compensatory metabolic alkalosis. This 
renal adjustment to hypercarbia is a "com-
promised adaptation' ' in which the respiratory 
acidosis is buffered by an increase in serum 
and extracellular bicarbonate, but this elevated 
bicarbonate in turn promotes a readjustment of 
the respiratory control mechanism favoring per-
petuation of the hypercapnic state. This effect 
of an elevated serum bicarbonate on the res-
piratory control mechanism has been demon-
strated in patients with and without respiratory 
compromise.3 Nocturnal hypercapnia in a pa-
tient with modest airway disease may initiate 
progressive elevation of the serum bicarbonate 
which in turn will alter the respiratory control of 
the central nervous system and lead to a sus-
tained elevation of arterial carbon dioxide ten-
sion during the waking hours . Furthermore, 
such an alteration prolongs the nocturnal ap-
neic spells increasing both the arterial hy-
poxemia and hypercapnia. 
This unfortunate situation may be magni-
fied by the administration of chloride-depleting 
diuretics that are often given for fluid retention. 
Clinical experience has impressed upon us the 
fact that patients with moderate-to-profound ar-
terial hypoxemia respond poorly to large doses 
of diuretics until their arterial oxygenation has 
been improved, which alone is often sufficient 
to promote a diuresis. The interrelationships 
among these abnormalities that occur during 
sleep are shown in Figure 1 . There are several 
points in this cycle in which the physician may 
intervene. The most quickly reversible problem 
is diuretic-induced alkalosis. When we encoun-
ter a patient with a marked elevation in serum 
bicarbonate who has been on chloride-deplet-
ing diuretics, we discontinue the diuretic ther-
apy and treat the patient with either a carbonic 
anhydrase inhibitor such as acetazolamide or 
by the administration of ammonium chloride. 
The effect of reducing the serum bicarbonate in 
a group of patients with severe obstructive lung 
disease whose metabolic alkalosis was in ex-
cess of that appropriate for the arterial carbon 
dioxide tension has been reported. 4 In these pa-
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Fig 1-Abnormalities of gas exchange during sleep. 
acetazolamide 500 to 750 mg/day in divided 
doses or ammonium chloride 3 to 6 gm/day in 
divided doses was administered until the serum 
bicarbonate, PaC02 and arterial pH stabilized . 
The effect of this therapy on the arterial blood 
gas composition of 11 patients is summarized 
in Table 1. 
Following the line of reasoning that a cen-
tral control mechanism may be abnormal in pa-
tients with prolonged nocturnal hypoventilation, 
a number of physicians in this field have been 
investigating the use of medroxyprogesterone. 
This agent has been used in an attempt to in-
crease minute ventilation in a variety of pulmo-
nary problems with variable success. The most 
striking benefit seems to occur in those patients 
whose apneic spells are limited to hypoventila-
tion on a central basis. Impressive improvement 
in arterial blood gas composition has been re-
ported in patients with obesity hypoventilation 5 
and chronic airway obstruction. 6 While correc-
tion of metabolic alkalosis and the use of pro-
gesterone can be of significant benefit to these 
patients, the administration of low-flow oxygen 
during sleep may be a necessary addition, es-
pecially for patients whose Pa0 2 when awake is 
less than 60 mm Hg. The effect of nocturnal ox-
TABLE 1 




HC03 mmol/L 36.9±1.7 28.1±1.0 
PaC02 , torr 60.8 ± 2.6 47.6 ± 2.2 
Pa02 , torr 52.4 ± 3.1 69.1±2.1 
MATHERS: CHRONIC AIRWAY OBSTRUCTION / 93 
TABLE 2 
Hypoxemia During Sleep in 10 Patients with C.O.A.D. on Room Air and Supplemental 0 2 
Sa0 2 Breathing Room Air Sa0 2 on 2L. 0 2 
AWAKE ASLEEP CHANGE AWAKE ASLEEP CHANGE 
-11 Mean 
S.D. 
95 68 - 26 97 86 
4 12 11 2 9 8 
ygen therapy has been described in a group of 
patients with moderate airway obstruction 
(Table 2)7 The data here are in terms of arterial 
oxygen saturation (Sa0 2 ) and not Pa02 . The 
mean waking arterial oxygen saturation was 
95% while the mean sleep saturation was 68% 
(a value associated with pulmonary arterial hy-
pertension and polycythemia). The administra-
tion of low-flow oxygen to this group of patients 
significantly improved the oxygenation during 
sleep. 
Abnormalities of ventilation during sleep 
remains a fertile field for investigation and the 
application of therapeutic modalities. We at the 
Medical College of Virginia are most interested 
in the documentation of breathing disturbances 
during sleep in patients believed to have accel-
erated physiologic deterioration. In conjunction 
with the Department of Neurology, we have de-
veloped a Sleep Study Center in which the pres-
ence of episodes of hypoventilation, central ap-
n ea or obstructive apnea may be readily 
determined and correlated with the stage of 
sleep. It is believed that after careful documen-
tation of these abnormalities and the application 
of appropriate therapy, we may significantly re-
duce the morbidity that develops in the group of 
patients with moderate airway obstruction and 
premature carbon dioxide retention . 
Respiratory Muscle Weakness 
A great deal has been learned about the 
function of the respiratory muscles in recent 
years. The ability of patients with obstructive air-
ways disease to sustain ventilation and avoid 
hypercapnic respiratory failure depends upon 
the strength and endurance of the respiratory 
muscles. The major causes of muscle failure in 
obstructive airways disease are ( 1) hyper-
inflation of the lung, (2) increase in airway resis-
tance increasing the work of breathing, and (3) 
generalized muscle weakness. The develop-
ment of respiratory muscle :failure may be di-
vided into two phases; muscle hypertrophy and 
muscle atrophy. 
In the early stages of airway obstruction, 
RESPIRATORY MUSCLE WEAKNEssl----------'"""'t'--------, 
/ 
+ MUSCLE LENGTH ~----HYPOXEMIA HYPERCARBIA 
l 
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Fig 2-The development of muscle weakness. 
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ALKALOSIS 
hyperinflation of the lung pushes down on the 
diaphragm shortening its resting length; as the 
muscle is progressively shortened, the ability to 
develop contractile force is reduced. At the 
same time, the increase in airway resistance 
and the increase in required minute ventilation 
increase the demands on this compromised 
muscle. In this early stage, it appears that there 
is hypertrophy of the diaphragmatic muscle. As 
the disease progresses, some patients begin to 
lose weight, most frequently because of in-
adequate diet, or an inability to eat a complete 
meal because of dyspnea. These patients de-
velop a negative nitrogen balance and their loss 
in general muscle mass is shared by the dia-
phragm, to the point of producing hypercapnic 
respiratory insufficiency. In the Pulmonary Func-
tion Laooratory we test inspiratory and ex-
piratory muscle strength with a pressure ma-
nometer but the presence of this problem can 
often be suspected during the physical exami-
nation by noting generalized muscle tone, evi-
dence of recent weight loss and asynchronous 
breathing. Asynchronous breathing develops 
when the diaphragm becomes so weak that it 
no longer acts as an inspiratory muscle with de-
pression of the abdominal contents and protru-
sion of the abdomen during inspiration. Instead, 
it becomes passive and is sucked up into the 
chest when the accessory muscles of in-
spiration are called into play causing retraction 
of the abdomen during inspiration . The events 
leading to this condition are seen in Figure 2 . 
There are a number of points of therapeu-
tic intervention. The increased airway resistance 
may be treated with bronchodilators and ag-
gressive airway hygiene to mobilize secretions. 
Hypoxemia may be reversed with supplemental 
oxygen, and malnutrition may be treated by en-
suring an adequate diet. Frequently, several 
small feedings, high in protein content, are nec-
essary in patients who become dyspneic during 
eating. Two other forms of therapy are currently 
under investigation and may add significantly to 
our management of these patients. One is 
breathing training and exercise programs; the 
other is the use of intermittent mechanical sup-
. port. The former may be useful in those patients 
whose condition is caused by purely mechani-
cal factors while the latter is reserved for those 
who have developed evidence of diaphragmatic 
atrophy. When a patient with evidence of 
marked muscle weakness is placed on either 
TABLE 3 
Investigation of .Hypercapnia 
Pulmonary Function Tests 
FEV 1 > 800 cc 
iPaC02 with Hyperventilation 
Metabolic Alkalosis 
1) Review diuretic use 
2) Seek history of sleep disturbance 
3) Obtain sleep study 
4) C02 response curve 
Muscle Weakness 
1) Obtain diet and weight history 
2) Examine for : 
a) Paradoxical abdominal motion 
b) Deltoid wasting 
c) Use of accessory muscles 
3) Request static muscle pressures 
4) lnspiratory /expiratory chest X-rays 
positive pressure ventilation or in the tank res-
pirator , there is a marked decrease in in-
spiratory muscle contractile effort and relief of 
dyspnea. Many physicians now feel that peri-
odic rest for this overworked muscle combined 
with an adequate diet will improve the patient 's 
ability to sustain ventilation. Patients with this 
problem are currently being managed at home 
with Drinker-type tank respirators in which they 
may sleep or spend several hours per day. The 
initial result of this therapy has been a marked 
reduction in the amount of hospitalization these 
patients require. 
In summary then, there are a number of 
factors, previously often unnoticed, that com-
plicate the clinical picture of chronic obstructive 
airway disease. With the recent advances in our 
knowledge and diagnostic techniques, we may 
more precisely define patients whose deteriora-
tion is premature. Premature deterioration may 
be suspected when the PaC02 is elevated in an 
individual whose FEV, is in excess of 800 cc 
and who is able to reduce the PaC02 with vol-
untary hyperventilation. The presence of sleep 
abnormalities, metabolic alkalosis or muscle 
weakness may then be confirmed by further in-
vestigation as outlined in Table 3. Appropriate 
therapeutic intervention may produce significant 
improvement in the patient 's condition and re-
duce the frequency of hospitalization . 
Table 1 is adapted by permission from the Canadian 
Medical Association Journal(11 7:900-903, 1977) 
Table 2 is adapted by permission from Annals of Inter-
nal Medicine(86 725-730, 1977). 
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Pre- and Postoperative Care of Pulmonary 
Patients Undergoing Nonthoracic Surgery 
R. PAUL FAIRMAN, M.D. 
Pulmonary Division, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth 
University, Richmond, Virginia 
Introduction 
A variety of pulmonary complications oc-
cur in patients during and following nonthoracic 
surgery. These may include hypoxemia, atelec-
tasis, bronchitis, pneumonia, and respiratory 
failure. The incidence of these complications is 
high and remains a major cause of morbidity 
and mortality in the postoperative state. Even 
so, this morbidity may be underestimated since 
hypoxemia, the most common pulmonary com-
plication, exerts its influence throughout many 
organ systems through inadequate tissue oxy-
genation. 
Physiologic Alterations Following Surgery 
Predictable alterations occur in the pulmo-
nary system in all patients undergoing surgery 
and general anesthesia regardless of age or un-
derlying illness; the major impairment is a re-
duction in lung volume. 1 Total lung capacity and 
all its subdivisions (vital capacity, residual vol-
ume, functional residual capacity, and other 
factors) are decreased; in addition, expiratory 
flows (FEV,) are reduced to a similar degree. 
These changes occur during the operative pro-
cedure, are maximal within the first 24 hours 
and slowly resolve over five to ten days. The 
magnitude of decline is related to the location of 
the surgical procedure; operations on the upper 
abdomen generally result in reductions of 50% 
to 60% . Following lower abdominal proce-
dures, lung volumes and flows decrease by 
Correspondence and reprint requests to Dr. R. Paul 
Fairman, Box 50, Medical College of Virginia, Richmond, 
VA 23298 
25%. There is no change in pulmonary function 
following operations on the extremities or the 
head and neck area. 
With the change in volume, the lung be-
comes less distensible (reduced compliance}, 
airways close and alveoli collapse, especially in 
dependent portions of the lung. Because of 
these abnormalities, there are areas in the lung 
in which ventilation is reduced but perfusion 
continues, resulting in hypoxemia. This de-
crease in arterial oxygen tension approximates 
20 torr following upper abdominal surgery in 
normal persons. 
Postoperatively, the respiratory rate in-
creases and tidal volume decreases, although 
total minute ventilation is unchanged. Periodic 
deep inspirations , such as with sighs and 
yawns, are less frequent also. This unvarying 
pattern of respiration leads to alveolar collapse 
and a progressive decline in compliance and ar-
terial oxygen tensions. These changes in res-
piratory pattern have been ascribed to post-
operative pain and poor moti on o f the 
diaphragm. However, administration of narcot-
ics to alleviate pain accentuates these changes 
as patients are reluctant to cough or take peri-
odic deep breaths. This leads to retention of se-
cretions, eventual atelectasis, and occasionally, 
pneumonia. 
Because of tissue repair and healing, the 
metabolic rate is increased following operative 
procedures, resulting in an increase in respira-
tory demands approximating 1 5% to 25%. In 
addition , the work of breathing is increased be-
cause of the fall in lung compliance. Thus, in 
the postoperative state, the respiratory system 
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TABLE 1 
Characteristics of Patients at High Risk for 
Postoperative Complications 
1 . Advanced age (>65) 
2. Obesity 
3. Past or present smoker 
4. Mucous hypersecretion 
5. Abdominal operation 
6. Postoperative FEV1 < 1.02 
7. C02 > 46 torr 
is called upon to meet greater demands at a 
time when it is temporarily impaired . These 
pathophysiologic events result in a small risk of 
complication in normal patients and a much 
greater risk in patients with preexisting pulmo-
nary disease. 
Factors Predisposing to Postoperative 
Complications 
Table 1 lists characteristics which pre-
dispose patients to postoperative complica-
tions. 2 Elderly patients have smaller lung vol-
umes and flow rates. Obesity decreases 
pulmonary compliance and reduces lung volumes 
and arterial oxygen tensions. Mucous hyper-
secretion (whether from smoking or other 
causes) reduces flow rates and predisposes to 
atelectasis and infection . Abdominal operations 
have significant effects on lung volumes as 
noted above. However, the most important fac-
tor contributing to postoperative complications 
is chronic obstructive lung disease. The vital ca-
pacities and flow rates are low in these patients, 
their work of breathing is increased and they are 
hypoxemic. In addition, a number of other fea-
tures in the patient with chronic lung disease 
add to the excessive risks for postoperative 
complications. These include mucous hyper-
secretion, abnormal mucociliary clearance 
mechanisms, and a propensity toward bron-
chospasm. In addition, a small percentage of 
patients have an elevated arterial carbon diox-
ide tension indicative of far-advanced pulmo-
nary dysfunction . 
Preoperative Evaluation 
Preoperative evaluation consists of the 
identification of those clinical features, func-
tional abnormalities and operative consid-
erations which are likely to lead to respiratory 
complications. Many predisposing factors can 
be identified by history and physical examina-
tion (age, weight, smoking, dyspnea, cough, 
and other findings). Similarly, operative factors 
such as the site of incision and the expected du-
ration of anesthesia should be identified in con-
sultation with the anesthesiologist and surgeon. 
Finally, an objective evaluation of lung volumes, 
air flow and gas exchange should be made. 
While many pulmonary function tests are avail-
able, simple spirometry and arterial blood gas 
evaluation are the most readily available and 
practical. The level of pulmonary dysfuriction is 
best evaluated with the FEV1 , although other 
spirometric tests have been used.3 An FEV1 less 
than one liter per second may be associated 
with carbon dioxide retention ; thus, a predicted 
postoperative FEV1 greater than this is desir-
able. A reasonable estimate of the post-
operative FEV 1 can be derived by multiplying 
the patient's preoperative value by the decline 
expected based upon the location of the opera-
tion. As an example, if the patient's pre-
operative FEV 1 were 2 liters and the con-
templated operation were a gastrectomy, one 
might expect a 60% reduction in FEV 1 . Thus, 
the estimated postoperative FEV1 would be 800 
cc and the patient's risk of respiratory fai lure 
high. Arterial blood gas analysis identifies pa-
tients with preexisting carbon dioxide retention 
and serves as a guide to oxygen supplementa-
tion. 
Preventive Measures 
Identification of patients at high risk is use-
ful only if measures are available which may 
prevent complications. Fortunately, specific pre-
and postoperative maneuvers in the high-risk 
patient have reduced the incidence of post-
operative complications from 66% to 21 % .4 A 
treatment program outline for preoperative, in-
traoperative, and postoperative care is pre-
sented in Table 2. For convenience, patients 
with COPD have been divided into four groups 
according to certain general characteristics; 
however, individual patients may fit into more 
than one category thus requiring more complex 
treatments as suggested in each specific cate-
gory. 
The first group includes patients with ob-
structive defects and also patients whose ven-
ti I a tory capacities are reduced from other 
causes such as restrictive defects, advancing 
age, obesity, or other factors. Patient education 
is very important; a knowledgeable patient is 
more likely to cooperate with difficult or uncom-
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GROUP 1 GROUP 2 
OBSTRUCTED HYPERSECRETION 
Instruction Stop smoking 













Treat cor pulmonale 
Correct metabolic alkalosis 
Insert arterial line 




Supplemental 0 2 
Care medication 
Continue preop program Maintain bronchodilators Continue ventilator 
Sputum smears 
fortable postoperative maneuvers aimed at pro-
tecting the respiratory system. Respiratory ther-
apists can be employed to teach deep 
breathing maneuvers and coughing techniques. 
The patient can be instructed in the use of an in-
spirometer, a device ~o ~ncourage maximum 
deep inspirations. Preoperative medications 
should be minimized; narcotics , ben-
zodiazepams and other sedative drugs reduce 
respiratory drive and result in the unvarying res-
piratory pattern which may lead to alveolar and 
airway collapse, a fall in compliance and arterial 
hypoxemia. The patient should be encouraged 
to sit and walk as soon as possible post-
operatively and the inspirometer should be 
used frequently. Suppl~mental oxygen should 
be administered until the patient has demon-
strated the ability to IT]fl.intain normal arterial ox-
ygen tensions breathing room air. In addition, 
postoperative medications which could poten-
tially suppress respiration should be given judi-
ciously. 
Those patients with mucous hyper-
secretion constitut~ woup 2. The major post-
operative respiratory complication in this group 
is atelectasis. Cessation of smoking will signifi-
cantly reduce the amount of bronchial secre-
tions. The duration of abstinence necessary for 
a significant change in the volume of secretions 
is highly variable; however, a period of five to 
seven days is usually sufficient. Every effort 
should be made to provide sufficient time prior 
to an operative procedure for clearing of the air-
ways. Chest percussion and postural drainage 
accelerate the clearing process, and hydration 
aids in liquefying and mobilizing secretions from 
the tracheobronchial tree. 5 Gram stains or cul-
Maintain arterial blood gases 
ICU 
ture of tracheobronchial secretions may reveal 
pathogenic organisms which should be treated 
with appropriate antibiotics. Operations should 
be scheduled for the afternoon; the morning is 
used in a vigorous attempt to remove any secre-
tions which may have accumulated during the 
preceding night. In the postoperative period , 
good tracheobronchial toilet should be main-
tained . In addition , sputum smears should be 
evaluated on a regular basis to guide antibiotic 
usage. 
Patients with bronchospasm (group 3) 
should also stop smoking, as cigarette smoke 
alone or in consort with other stimuli often in-
duces bronchospasm. Bronchodilators should 
be administered preoperatively in therapeutic 
doses. Aminophylline and beta adrenergic 
agents are first-line drugs. Systemic steroids 
may be necessary in patients who have re-
quired their use in the past. Steroids must be 
given in those patients who require them on a 
routine basis for adequate bronchodilatation. 
Patients in group 4 are those whose pre-
operative arterial carbon dioxide tensions are 
elevated and those who are likely to develop 
elevations because of the expected decline in 
their pulmonary function following surgery. Be-
cause the etiology of the respiratory failure is 
known (surgery) and improvement likely, the 
episodes should be managed with little diffi-
culty. Preoperatively, cor pulmonale should be 
treated with diuretics and the administration of 
supplemental oxygen to correct pulmonary hy-
pertension and relieve right heart failure. Diu-
retic and steroid administration may produce 
metabolic alkalosis which should be corrected 
since it depresses respiratory drive. During the 
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intraoperative period, an arterial line should be 
inserted for repeated measurements of arterial 
blood gases. The physician can then make ap-
propriate changes in the ventilator settings to 
maintain adequate levels of arterial oxygen ten-
sion and baseline levels of arterial carbon diox-
ide. In particular, intraoperative hyperventilation 
should be avoided, as it leads to relative hypo-
ventilation in the postoperative period as body 
tissue stores of carbon dioxide are replaced . In 
the postoperative period, ventilatory support 
should continue until the patient has demon-
strated the ability to maintain his own ventila-
tion. This type of care is given preferably in an 
intensive care unit where acute exacerbations 
of chronic respiratory failure are best managed. 
Conclusions 
The patient evaluation and respiratory 
care program outlined here provides a measure 
of protection for patients with preoperative pul-
monary dysfunction. Such a program can be in-
stituted with equipment now available and little 
added time, and if done routinely and diligently, 
leads to a reduction in postoperative complica-
tions. In addition, patients who in previous years 
~ 
might have been considered "too sick" for op-
eration can now be managed through a post-
operative period without significant morbidity 
and/or mortality. 6 .... 
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Pulmonary Rehabilitation in a Community 
Hospital 
RAYMOND J. CASCIARI, M.D. 
PATRICIA FERGUSON, R.N . 
Pulmonary Rehabilitation, St. Joseph Hospital, 1100 West Stewart Drive, Orange, California 
Pulmonary rehabilitation programs seem 
to have come into vogue along with the national 
craze for exercise. This paper will discuss the 
feasibility of a rehabilitation program in a com-
munity hospital. In order to do that, we will first 
address several questions: "Does pulmonary 
rehabilitation really work?" ; " If so, how? "; and 
" Is it safe?" Having answered those questions, 
we will discuss some of the details of setting up 
a rehabilitation program . 
"Does Pulmonary Rehabilitation Really 
Work?" 
Several investigators have shown signifi-
cant improvement in exercise tolerance follow-
ing pulmonary rehabilitation programs con-
sisting of a number of treatment modalities 
which include bronchodilator therapy, antibiotic 
therapy, oxygen, postural drainage, somatic 
(exercise) reconditioning, and breathing retrain-
ing.1 -4 Petty et al5 showed not only an increased 
exercise tolerance but also improved survival, 
reduction in hospital days and improved psy-
chological status in patients completing a reha-
bilitation program. Pierce and associates6 have 
shown that , following exercise training, maximal 
oxygen consumption was higher and, at any 
given level of exercise, minute ventilation, oxy-
gen consumption and heart rate were .lower 
even though there was no improvement in ven-
tilatory function or lung volumes. Others have 
confirmed the beneficial effects of recondition-
ing without breathing retraining. 7- 11 
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Although there is general agreement that 
exercise reconditioning is effective, even in pa-
tients with severe chronic obstructive pulmonary 
disease, there is no consensus regarding the 
value of breathing retraining. The studies ap-
pearing in the literature consist of several treat-
ment modalities applied simultaneously; thus it 
is impossible to separate the relative effects of 
breathing retraining . Pursed lip breathing and 
abdominal augmentation can affect a decrease 
in minute ventilation and respiratory rate and an 
increase in tidal volume as well as an improve-
ment in blood gas tensions. 12-14 Motley 15 found 
that slow deep breathing led to a reduction in 
the ratio of dead space to tidal volume and an 
increase in the oxygen saturation in most pa-
tients with emphysema. Following a program of 
breathing retraining, Sinclair reported a reduc-
tion of inefficient spinal and shoulder girdle 
movement during respiration .16 
At the University of California at Irvine we 
have recently completed a study that was de-
signed to separate the relative effects of so-
matic reconditioning and breathing retraining . 
Results of this study have been submitted else-
where for publication. Our program was divided 
into four phases: selection of patients, opti-
mizing medical therapy, somatic reconditioning, 
and breathing retraining. Eleven patients with 
severe type A chronic obstructive pulmonary 
disease were selected for this study. Optimal 
medical management using bronchodilators, 
oxygen, diuretics and ionotropics where appro-
priate was achieved and stabilized prior to en-
tering the study. The patients were then exer-
cised on a treadmill on an outpatient basis three 
times weekly in pairs with one patient resting 
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Fig 1-Mean percent change in maximal exercise tolerance for all 11 patients over the entire study period. Time o is deter-
mined to be the point at which breathing retraining has begun. 
while the other was exercising . The total exer-
cise session for two men would last one hour 
with each man exercising for approximately 25 
minutes. Each exercise session consisted of a 
warm-up period at slow speeds! a stress period 
during which the patient would be encouraged 
to top his previous maximal tolerance, rest, and 
then several longer exercise periods at lower 
workloads. The rest periods were long enough 
to let the patient's pulse and respiratory rate re-
turn to baseline levels. The patients continued 
exercising until their maximal exercise tolerance 
was stable for at least four consecutive ses-
sions. 
After the somatic reconditioning phase of 
the program was completed, a program of 
breathing retraining was begun. Breathing re-
training consisted of education about chronic 
obstructive lung disease, pursed lip breath-
ing, 1 2 · 1 3 expiratory abdominal augmentation, 14 
synchronization of movement of the abdomen 
and thorax using magnetometry and biofeed-
back, relaxation techniques for the accessory 
muscles 1 7 using electromyography and biofeed-
back, and psychological reassurance. Attempts 
were made to teach the patients to integrate 
these breathing retraining techniques into their 
activities of daily living . Breathing retraining was 
continued until all the techniques were well 
learned and were used without prompting dur-
ing exercise as well as at rest. 
There was significant improvement in ex-
ercise tolerance with somatic reconditioning 
alone (Fig 1 ). The average percent improve-
ment in estimated oxygen consumption, which 
is a measure of work tolerance, after somatic 
reconditioning was 71 % [0.97 ± 0.41 liters/ 
min to 1 .52 ± 0.43 liters/min (p < 0 .005)]. 
What was surprising, however, was that there 
was an additional 39% increase in exercise tol-
erance after breathing retraining [1 .52 ± 0 .43 
liters/min to 2.12 ± 0.61 liters/min (p < 
O. O 2 5 )]. The patients differed in their response 
to the program. Some improved minimally after 
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exercise reconditioning but markedly after 
breathing retraining. Others improved more af-
ter exercise reconditioning. The mean improve-
ment from baseline levels after completion of 
the program was 1 26%. These results indicate 
that somatic reconditioning and breathing re-
training are beneficial aspects of a program of 
pulmonary rehabilitation. 
"If So, How?" 
Based upon earlier work, the improve-
ment after exercise reconditioning was ex-
pected. It is generally accepted that this im-
provement is due to a combination of improved 
neuromuscular coordination and acclimatization 
to walking on a treadmill, improved utilization 
and distribution of delivered oxygen, and im-
proved effort due to motivational factors. 1 5 .7. 9 
The improvement after breathing retrain-
ing is more difficult to explain and has not been 
previously reported in the literature; it could not 
be attributed to any improvement in resting pul-
monary function since none was found. Most 
previous workers have not found any change in 
resting pulmonary function 1 ·6 - 8 following a pro-
gram of pulmonary rehabilitation, and our study 
substantiated these findings. 
Arterial blood gas studies showed that the 
Pa02 did increase significantly from the recon-
ditioning to the retraining phase. This indicates 
better ventilation-perfusion relationships follow-
ing breathing retraining . We could not, how-
ever, attribute the improvement observed in ex-
ercise tolerance to this increase in Pa02 alone, 
since the improvement in oxygen content would 
not be great enough to account for the improve-
ment in exercise tolerance. Arterial blood gas 
studies also showed that there was a significant 
decrease in the base excess after breathing re-
training compared to both the baseline period 
and the reconditioning period. This indicates 
that the patients were willing to exercise beyond 
their anaerobic threshold following breathing re-
training. This would increase exercise toler-
ance; however, it is again unlikely that this 
would account for all the improvement we ob-
served. 
The heart rate did not change significantly 
during the study (Fig 2). However, the respira-
tory rate decreased significantly following 
breathing retraining both at rest and after maxi-
mal exercise. When examined further it became 
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Fig 2-Heart rate and respiratory rate at rest and after max-
imal exercise measured at the beginning of the study, after 
somatic reconditioning and after breathing retraining. 
was due to an increase in tidal volume, because 
minute ventilation did not change significantly. 
Cherniack18 has shown that there is a de-
creased efficiency of the respiratory muscles 
and a high oxygen cost of increased ventilation 
in patients with emphysema. It has been sug-
gested that breathing retraining may decrease 
the work of breathing by lowering the respira-
tory rate and relaxing accessory muscles. 1 · 1 6 
The most likely explanation for the improvement 
demonstrated by our study after breathing re-
training is increased efficiency of the respiratory 
muscles so that there is less relative increase in 
the oxygen cost of increasing ventilation during 
exercise, thereby freeing more oxygen for distri-
bution to the peripheral tissues. 
This study also showed that sophisticated 
and expensive magnetometry monitoring is not 
necessary for the purpose of synchronizing 
chest and abdominal movement. We found that 
patients corrected their own phase lag following 
somatic reconditioning and that the magneto-
metry and biofeedback techniques were not 
needed. 
Ten of the 11 patients responded to a 
questionaire that was sent to them at the con-
clusion of the study. All felt that they had bene-
fited from the study (8 answered " very much" 
and 2 answered " a lot"). Their comments re-
garding how they benefited are interesting . In 
response to the question "What can you do 
now that you could not do before the pro-
gram?'' two persons said that they could re-
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sume work, two said they were able to travel 
(one having completed a cross-country trip) , 
one began to play golf again, one reported the 
ability to shop for himself , and one related he 
TABLE 
Comprehensive Respiratory Care: Factors to Consider 
I. General 
A. Environmental factors 
1 . avoid inhalation of pollutants, including ciga-
rette smoke 
2. avo id occupational hazards 
3. consider climate (altitude, temperature , humid-
ity , smog) 
B. High fluid intake, unless contraind icated by pres-
ence of cardiac disease 
C. Yearly influenza shot 
D. Pneumococcal vaccine shot 
II. Medications 
A. Bronchodilators 
1 sympathomimetics (prefer beta2 stimulators) 
2. theophylline types 
B. Expectorants 
1. water 
2 . glyceryl guaiacolate 
3. other 
C Antim icrobials (early antibiotic therapy for pulmo-
nary infections) 
D. Corticosteroids 
E. Dig italis 
F. Diuretics 
G. Cromolyn sodium 
H. Other 
Ill. Respiratory Therapy 
A. Aerosol devices 
1 . cartridge inhaler 
2. hand-held nebulizer 
3. compressor-driven nebulizer 
4 . Intermittent positive pressure breathing 
B. Humidification devices 
1 . vaporizer / humidifier 
2. al l-purpose nebulizer (heated or cool mist) 
3. ultrasonic nebulizer 
C Oxygen systems 
1 . high-pressure gas cylinders (stationary or port-
able) 
2. low-pressure liquid systems (stationary or port-
able) 
3. concentrators 
D. Air purifiers 
IV . Physical Therapy 
A Somatic (exercise) reconditioning 
B. Breath ing retraining 
C. Percussion and postural drainage 
V. Occupational Therapy 
A. Activities of daily living 
B. Energy conservation 
C. Adaptive equipment 
VI. Nutrition 
VII. Psychosocial Evaluation and Recommendations for 
Vocational Rehabi litation 
VIII. Patient and Family Education 
was able to walk up a small hill to a recreation 
center that he had not been able to climb for the 
previous three years. Four patients suggested 
that the most important benefit of the program 
was learning that they could recover from a 
stressful situation, thereby decreasing their 
sense of panic. These findings , suggestive of 
subjective improvement, are similar to almost 
every study of pulmonary rehabilitation that has 
appeared in the literature. 1 ·4 .7 10 This improve-
ment may be secondary to the physiologic 
changes already described , or it may represent 
benefits obtained by the patients from the 
amount of attention rendered to them by mem-
bers of the rehabilitation team . In any event, it 
seems to be a real and consistent finding follow-
ing programs of pulmonary rehabilitation . 
"Is It Safe?" 
No complications of exercise were ob-
served in our study; indeed , not a single study 
has reported deterioration of cardiopulmonary 
function following a program of pulmonary reha-
bilitation . There has been no precipitation of 
right cardiac failure ; to the contrary , a fall in 
mean resting pulmonary artery pressure along 
with a rise in arterial oxygen partial pressure has 
been reported . 1 9 
How to Set Up a Program in a Community 
Hospital 
Equipment and Physical Plan 
Approximately 400 sq ft is needed to 
house a rehabilitation program, one easily ac-
cessible from a hospital entrance or the parking 
area. The room should be divided so that there 
is an area where patients can exercise and an 
area where the physician can examine prospec-
tive patients. Since patients will be exercising 
rather strenuously, the room must be well venti-
lated . 
We elected to use a treadmill to recondi-
tion our patients . We chose this because tread-
mill walking more closely approximates day to 
day activity than bicycle ergometry. A cardiac 
monitoring system, complete with recorder, is 
mandatory , as is a fully equipped resuscitation 
cart. Oxygen is , of course, available and we try 
to have several different types on hand to in-
struct the patients in their use. A Hewlett-Pack-
ard ear oximeter is an excellent way of measur-
ing oxygen saturation noninvasively . 20 This 
essentially negates the need for arterial line 
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monitoring. The ear oximeter attaches to the 
patient's ear and gives continuous saturation 
readouts at rest, while exercising and during re-
covery. All of the equipment described above 
can be obtained for less than $15,000. 
Personnel 
The rehabilitation team consists of a medi-
cal director, a rehabilitation specialist who may 
be a registered nurse, a respiratory therapist or 
a physical therapist, a social worker, and in 
some instances an occupational therapist and a 
psychologist. The medical director performs a 
complete history and physical on all candidates 
referred to the program. He also supervises and 
interprets the exercise stress test and the pul-
monary function tests, and documents the de-
gree of the patient's disability. A useful checklist 
illustrating the comprehensive approach to the 
patient with chronic obstructive pulmonary dis-
ease is shown in the Table. Various aspects of 
this program can be implemented by the physi-
cian directly; however, many aspects, including 
techniques of avoidance of cigarette smoke, 
nutritional information and family education, are 
better performed by other members of the reha-
bilitation team . The physician sees the patient at 
the conclusion of the program and at scheduled 
follow-up sessions at 6 weeks, 6 months, 1 2 
months, 1 8 months and 24 months after com-
pletion of the program. 
Pulmonary Stress Testing 
Stress testing can be performed on either 
a bicycle ergometer or on a treadmill. Cardiac 
status and oxygen saturation are monitored 
continuously. The test consists of graded exer-
cise with the patient walking at each level for 
three minutes. Since most of our patients have 
severe exercise limitation, we have arbitrarily 
elected to begin our stress testing at much 
lower workloads than the accepted protocols 
for cardiac disease. The patient is started at 1 
mph and a 0% grade for three minutes. The 
speed is then increased by 1 mph every three 
minutes until the patient reaches 3 mph at a 0% 
grade for three minutes at which point the grade 
is increased to 6%. The grade is then increased 
by 2% increments every three minutes until the 
patient reaches his maximal exercise tolerance. 
The patient is then allowed to recover until his 
heart rate and respiratory rate have returned to 
baseline levels. If the patient's saturation falls 
below 88%, the test is repeated with oxygen in 
place administered by nasal cannula and 
started at 2 liters/ min. The stress test is re-
peated, increasing the oxygen by increments of 
1 liter /min , until the patient's saturation re-
mains above 88% at maximal exercise. 
The typical patient with severe chronic ob-
. structive pulmonary disease will stop exercising 
at a heart rate that is well below his predicted 
maximum. Additionally , he will show some 
desaturation with respect to oxygen . If the pa-
tient stops exercising when his heart rate has 
reached his predicted maximum, one must con-
sider either primary cardiac disease or extreme 
deconditioning as the cause of the patient 's ex-
ercise limitation. 
The stress test as described above is a 
valid indicator of the need for home oxygen . Pa-
tients who desaturate severely with maximal ex-
ercise are also likely to need oxygen during 
sleep and meals. An exact prescription can be 
written based on the oxygen saturation as ob-
served during the treadmill stress test. 
The Program 
Many different types of programs exist. 
We feel that six weeks is a reasonable length of 
time to accomplish both somatic reconditioning 
and breathing retraining. We also favor an out-
patient program as opposed to inpatient rehabil-
itation, as outpatient rehabilitation enables the 
patient to incorporate the techniques taught into 
his activities of daily living. In addition, there is 
more time in a six-week program than in a two-
week inpatient program for problems of day-to-
day living to become apparent to the patient 
and the rehabilitation team. Our patients come 
to the hospital three times a week for one hour 
sessions. Each patient has a partner, and in-
deed the support of a partner seems to be a 
very important part of the psychological reas-
surance. Somatic reconditioning and breathing 
retraining are begun simultaneously and are en-
forced throughout the program. Breathing re-
training emphasizes primarily pursed lip breath-
ing, accessory muscle relaxation , abdominal 
augmentation and psychological reassurance. 
The program is tailored to the individual patient 
utilizing the expertise of physical therapy, occu-
pational therapy and social services as in-
dicated by the weekly reviews of each patient 's 
case. 
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In conclusion, rehabilitation has been 
shown to be an effective and safe art of medical 
practice that can return a patient to his highest 
possible functional capacity. Pulmonary rehabil-
itation programs should include careful and op-
timal medical management, somatic recondi-
tioning, and breathing retraining which can be 
performed in a community hospital without ex-
pensive or invasive monitoring. If properly car-
ried out, such programs will result in increased 
exercise tolerance, improved sense of well 
being, and reduced hospitalization. 
Acknowledgments: We wish to thank 
Jackie Gardiner for her assistance in typing this 
manuscript. 
REFERENCES 
1. GUTHRIE AG, PETTY TL: Improved exercise tolerance in 
patients with chronic airway obstruction. Phys Ther 
50:1333-1337 , 1970. 
2. FISHMAN DB, PETTY TL: Physical, symptomatic and 
psychologic improvement in patients receiving com-
prehensive care for chronic airway obstruction. J 
ChronicDis 24775-785, 1971 . 
3. KIMBEL P, KAPLAN AS, ALKALAY I, ET AL: An in-hospital 
program for rehabilitation of patients with chronic ob-
structive pulmonary disease. Chest 60:(Suppl 2)6S-
1OS,1971. 
4. SHAPIRO BA, VOSTINAK-FOLEY E, HAMILTON BB, ET AL: 
Rehabilitation in chronic obstructive pulmonary dis-
ease: A two-year prospective study. Resp Care 
22:1045-1057 , 1977. 
5. PETTY TL, NETT LM, FINIGAN MM, ET AL: A comprehen-
sive care program for chronic airway obstruction. 
Methods and preliminary evaluation of symptomatic 
and functional improvement. Ann Int Med 70: 11 09-
1120, 1969. 
6. PIERCE Af<, TAYLOR HF, ARCHER AK, ET AL: Response 
to exercise training in patients with emphysema. Arch 
Int Med 113:78-86, 1964. 
7. NICHOLAS JJ, GILBERT R, GABER, ET AL: Evaluation of 
an exercise therapy program for patients with chronic 
obstructive pulmonary disease. Am Rev Resp Dis 
102:1-9, 1970. 
8. MERTENS DJ, SHEPHARD RJ, KAVANAGH T: Long-term 
exercise therapy for chronic obstructive lung disease. 
Respiration 35:96-107, 1978. 
9. PAEZ PN, PHILLIPSON EA, MASANGKAY M, ET AL: The 
physiologic basis of training patients with emphysema. 
Am Rev Resp Dis 95:944-953, 1967. 
1 0. BASS H, WHITCOMB JF, FORMAN R: Exercise training: 
Therapy for patients with chronic obstructive pulmo-
nary disease. Chest 57:116-121 , 1970. 
11 . VY AS MN' BANISTER EW' MORTON JW' ET AL: Response 
to exercise in patients with chronic airways obstruction. 
I. Effects of exercise training. Am Rev Resp Dis 
103:390-399, 1971. 
12. THOMAN AL, STOKER GL, Ross JC: Efficacy of pursed-
lips breathing in patients with chronic obstructive pul-
monary disease. Am Rev Resp Dis 93: 1 00-1 06, 
1966. 
13. MUELLER RE, PETTY TL, FILLEY GF: Ventilation and arte-
rial blood gas changes induced by pursed lip breath-
ing. J Appl Physiol 28:784-789, 1970. 
14. PETTY TL, GUTHRIE A: The effect of augmented breath-
ing maneuvers on ventilation in severe chronic airway 
obstruction. Resp Care 16:104-111 , 1971. 
1 5. MOTLEY HL: Effects of slow deep breathing on the 
blood gas exchange in emphysema. Am Rev Resp Dis 
88:484-492, 1963. 
1 6. SINCLAIR JD: Effect of breathing exercises in pulmonary 
emphysema. Thorax 10:246-249, 1955. 
17. CHERNIACK RM, CHERNIACK L, NAIMARK A: Respiration 
in Health and Disease, ed. 2. Philadelphia, WB Saun-
ders Company, 1972, p 443. 
18. CHERNIACK RM: The oxygen consumption and effi-
ciency of the respiratory muscles in health and emphy-
sema. J Clin Invest 38:494- 499, 1959. 
19. DEGRE S, SERGYSELS R, MESSIN R, ET AL: Hemo-
dynamic responses to physical training in patients with 
chronic lung disease. Am Rev Resp Dis 11 0:395-
402, 1974. 
20. SAUNDERS NA, POWLES ACP, REBUCK AS: Ear Oxi-
metry: Accuracy and practicability in the assessment 
of arterial oxygenation. Am Rev Resp Dis 113:745-
749, 1976. 
1 06 / CASCIARI AND FERGUSON: PULMONARY REHABILITATION 
Newer Drugs and Their Use in the 
Treatment of Bronchial Asthma 
ORHAN MUREN, M.D. 
Professor of Medicine, Medical College of Virginia, Health Sciences Division of Virginia 
Commonwealth University, Richmond, Virginia 
The current knowledge of patho-
physiology and new medications, as well as the 
better use of old ones, has significantly im-
proved the therapy and prognosis of patients 
with bronchial asthma. However, it should be 
understood that drug therapy is beneficial only 
when aggravating or precipitating agents have 
been eliminated from the patient's environment; 
these include allergens, such as dust, mold, 
pollens and other irritants, infection, exercise, 
psychological disturbances, certain drugs (aspi-
rin}, and stimulation of irritant receptors in the 
respiratory tract. 
There are five major classes of drugs used 
in treating bronchial asthma: ( 1) adrenergic 
agents, (2) xanthines, (3) corticosteroids, (4) 
cromolyn sodium, and (5) parasympatholytic 
agents. Some adrenergic agents, such as ter-
butaline and metaproterenol, offer advantages 
over others, such as epinephrine, isoproterenol 
and ephedrine. Among the xanthines the mea-
surement of theophylline blood levels has re-
sulted in the more effective use of aminophylline 
and other theophylline compounds. The devel-
opment of a topical steroid, beclomethasone, 
has been useful in treating steroid-dependent 
chronic asthmatics. The drugs described below 
are prescribed to eliminate wheezing and dysp-
nea; however, other types of therapy such as 
antibiotics for infections, hyposensitization for 
allergic factors, and counseling for emotional 
disturbances should also be considered. 
Correspondence and reprint requests to Dr. Orhan 
Muren, Box 4 72, Medical College of Virginia, Richmond, 
VA 23298. 
Adrenergic Drugs 
Adrenergic agents reduce bronchial ob-
struction by activating the enzyme adenylcy-
clase, which increases cyclic adenosine mono-
phosphate (cAMP) in bronchial smooth muscle 
and mast cells. Adrenergic drugs have alpha-
and beta-stimulating effects. The stimulation of 
alpha receptors causes vasoconstriction. Beta 
receptors are divided into beta, and beta2 re-
ceptors. The stimulation of beta, receptors 
causes cardiac stimulation; stimulation of beta2 
receptors is responsible for bronchodilatation, 
as well as other effects. Terbutaline and me-
taproterenol are primarily " beta2-selective," but 
they also stimulate the heart minimally. 
Terbutaline (Brethine; Bricanyl}, which 
comes i·n tablets and ampules is, as noted 
above, a selective beta2 agent. The most com-
mon side effect is tremor, which is caused by 
stimulation of beta2 receptors in the skeletal 
muscle. It is recommended that this drug be 
started at 2.5 mg every eight hours. Tremor 
may disappear after continuation of the medica-
tion; thereafter the dose can be increased to 5 
mg every eight hours. However, it should be 
kept in mind that an injection dose of 0.25 mg 
of terbutaline may also cause a significant de-
gree of cardiac stimulation. 
Metaproterenol (Alupent) is available as 
a syrup, in tablets and as an aerosol; tremor is a 
common side effect. The usual oral dose is 1 0 
to 20 mg q.8.h. 
lsoetharine (Bronkosol; Bronkometer) is 
available as an aerosol. 
Epinephrine and isoproterenol have 
been used for a long time in the management of 
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patients with bronchial asthma. Epinephrine has 
both alpha- and beta 1- and beta2-stimulating ef-
fects. lsoproterenol stimulates both beta 1 and 
beta2 receptors. Epinephrine may also improve 
symptoms by constricting vessels in the bron-
chial mucosa, thus decreasing edema. How-
ever, epinephrine increases blood pressure, 
and large doses of this agent or isoproterenol 
can cause angina pectoris and cardiac ar-
rythmias. It has been observed that cardiac 
stimulation may increase blood flow in some re-
gions of the lung where there may be poor ven-
tilation. This may cause lowering of arterial 0 2 
tension. 
Ephedrine. This drug was the first adren-
ergic agent used and it stimulates both alpha 
and beta receptors. However, its bronchodilata-
tion activity is less than that of the new beta2 
agents. Ephedrine may increase blood pressure 
and may cause CNS stimulation (insomnia, ner-
vousness). It may be responsible for urinary re-
tention in patients with some degree of prostatic 
obstruction. Ephedrine and isoproterenol have 
more beta- 1 (cardiac stimulation) than the newer 
medications . Insomnia, palpitations, and anx-
iety limit their use in bronchial asthma. 
Xanthines 
Theophylline is 1 ,3 dimethylxanthine. 
Methylxanthines increase intracellular cAMP by 
inhibiting phosphodiesterases , enzymes re-
sponsible for the breakdown of cAMP. Theoph-
ylline has been used for many years in com-
bination with ephedrine and a sedative. The 
combination medications provide one fourth to 
one half the proper dose of theophylline and 
less bronchodilatation. 
Aminophylline is theophylline ethylene-
diamine and is used more often than the-
ophylline itself . Since the difference between 
therapeutic and toxic doses of theophylline 
compounds may be narrow, it is desirable to 
start with a small dose and increase it as re-
quired . Plasma theophylline levels should be 
obtained if patients do not respond to the usual 
doses; the optimum serum level is between 1 0 
and 20 µg / ml. 1 Patients with chronic liver dis-
ease should be treated carefully, since the-
ophylline is detoxified in the liver. Serum the-
ophylline levels greater than 20 µg/ml are 
usually associated with toxic side effects, such 
as nausea, vomiting, anorexia, headache, tachy-
cardia and CNS irritation . Levels greater than 
30 to 40 µg / ml may lead to serious cardiac ar-
rythmias and seizures. 
An oral loading dose of approximately 5 
to 6 mg/kg of aminophylline, anhydrous the-
ophylline, or elixophylline will supply therapeutic 
theophylline levels within 30 to 45 minutes and 
will usually be effective against a mild-to-moder-
ate degree of bronchospasm. In cases of se-
vere bronchospasm 6 mg/kg aminophylline 
should be given intravenously in a drip over 20 
minutes. 
The usual recommended intravenous (IV) 
maintenance of theophylline is 0 .9 mg/kg/hr 
aminophylline. Serum theophylline levels should 
be checked at 1 8 to 24 hours and proper ad-
justments made as needed. In patients with 
congestive heart failure or liver disease, the 
dose should be reduced by half or more if in-
dicated. In elderly people intravenous mainte-
nance of theophylline is 0. 7 mg/kg/hr. 
For long-term maintenance of theophylline 
an average-size adult patient with bronchial 
asthma requires approximately 800 to 1 200 
mg/day aminophylline. The serum levels 
should be checked after three days on this ther-
apy, and proper adjustments should be made to 
maintain levels between 1 0 to 20 µg/ml. The 
slow-release preparations of theophylline can 
be given every 1 2 hours and can be effective 
against early-morning bronchospasm . 
Corticosteroids 
Steroids are very useful in the treatment of 
asthma but should be used only when conven-
tional bronchodilating agents fail to relieve bron-
chospasm. Some of the undesirable side effects 
of steroids include acne, peptic ulcer, osteo-
porosis, growth retardation , hypertension, adre-
nal suppression and opportunistic infections. 
The exact mechanism of steroid action in 
asthma is not definitely known . Large doses ap-
pear to potentiate beta agonists and cause 
bronchodilatation. As soon as symptoms are re-
lieved with up to 60 to 80 mg/day of predni-
sone or prednisolone , the dose is tapered to the 
smallest effective dose, 5 to 1 0 mg/day or 1 0 
to 20 mg every other day. 
Beclomethasone dipropionate (Van-
ceril) is a topically active, inhaled steroid (50 
µg/puff , 8 to 20 puffs per day). When used 
properly it has no, or only minimal, systemic ef-
fects and is especially useful in steroid-depen-
dent chronic asthmatics. It is most effective 
1 08 / MUREN : THERAPEUTIC DRUGS FOR BRONCHIAL ASTHMA 
when the patient is relatively free of asthma. 
The usual dose is two puffs four times a day. 
The patient continues to take all previous medi-
cations. If the patient improves after two weeks, 
steroids should be decreased slowly. If no im-
provement takes place, the dosage may be in-
creased to four puffs four times a day and then 
decreased after two weeks of symptomatic im-
provement. Sixteen hundred micrograms or 
greater per day causes adrenal suppression . By 
proper administration of beclomethasone in 
many steroid-dependent asthmatics, the steroid 
dose can be significantly reduced and even dis-
continued . The main possible adverse effects of 
this agent are nasopharyngeal candidiasis and, 
in patients who have been on long-term sys-
temic steroids, adrenocortical insufficiency as 
adrenal suppressive doses of corticosteroids 
are decreased . Oral candidiasis can be mini-
mized by rinsing the oral cavity after each use 
with plain water ; if candidiasis occurs, nystatin 
(Mycostatin) rinse three times a day will eradi-
cate the infection . 
Cromolyn Sodium 
Cromolyn blocks the release of chemical 
mediators from the sensitized mast cells; it has 
no antihistamine, bronchodilator or anti-inflam-
matory characteristics and should not be used 
during an acute asthmatic attack. It has only 
prophylactic value. The main indication in the 
asthmatic appears to be as a steroid-sparing 
agent. It is most useful in young patients with 
extrinsic or exercise-induced asthma. The usual 
dose is 20 mg four times a day by a special in-
haler. 2 If after four weeks of therapy, no im-
provement occurs, the drug should be discon-
tinued. The adverse side effects include cough, 
th roat irritation, skin rashes, occasionally bron-
chospasm, and eosinophilic pneumonia. 
Parasympatholytic Agents 
A parasympatholytic agent, such as iprat-
ropium (SCH-1 000/ Atrovent , 40 µg/puff) may 
give bronchodilatation in asthma and chronic 
bronchitis. It is not available in the United States 
at the present time. 
Combination of Drugs 
A beta agonist such as terbutaline can be 
given with theophylline, and lower doses of the 
two together may be as effective or less toxic 
than higher doses of either drug alone. Oral 
bronchodilating agents are usually continued 
when patients receive corticosteroids or cromo-
lyn sodium . 
Indications of Severity of Bronchial Asthma 
Significant reduction in FEV 1 (less than 
1 . 0 liter) associated with one or more abnormal-
ities such as marked scalene muscle con-
tractions, mental confusion , pulse rate greater 
than 130/min, pulsus paradoxus greater than 
1 0 mm Hg , marked overdistension of the 
lungs on chest x-ray, central cyanosis, arterial 
PC02 greater than 40 mm Hg, pneumothorax, 
or pneumomediastinum, indicate a severe at-
tack of asthma.3 If FEV1 is less than 25% pre-
dicted, there is a tendency to C02 retention . 
Pulsus paradoxus of more than 1 0 torr is asso-
ciated with FEV1 less than 25% predicted ; sca-
lene muscle contractions and intercostal retrac-
tions suggest FEV 1 less than 1 .0 liter.4 
Patients with these abnormalities should 
be hospitalized immediately, and receive proper 
therapy (IV aminophylline, high doses of ste-
roids, supportive and specific care) . 
Status asthmaticus is defined as a severe 
asthma attack unresponsive to inhaled or in-
jected sympathomimetic amines. The corner-
stone of management of status asthmaticus is 
the administration of IV aminophylline and large 
doses of corticosteroids. Supportive care and 
specific therapy for any complication should 
also be undertaken. 
Indications for Intubation and Mechanical 
Ventilation in Asthma. 
1 . Arterial PC02 over 50 to 60 torr in the 
absence of chronic hypercapnea. 
2. An arterial P02 under 60 torr on 6 lit-
ers of 0 2 by nasal cannula. 
3 . Evidence of marked increase in the 
work of breathing judged by physical 
examination, even in the presence of 
near-normal arterial gas studies. 
4. Respiratory arrest. 
It should be emphasized that during the 
acute episode of an asthma attack, there is a 
lowering of arterial P02 and PC02 . Perfectly 
normal PC02 such as 40 torr indicates fatigue 
of the patient and the necessity of aggressive 
therapy. 
Treatment Failures 
Patient compliance and understanding are 
important for the successful management of 
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asthma. Hidden environmental hazards should 
be eliminated. Not every wheezing represents 
bronchial asthma; left-sided heart failure , 
chronic obstructive pulmonary disease, pulmo-
nary emboli, hypersensitivity pneumonitis, medi-
astinal node compression, foreign body in a 
large bronchus, or bronchial carcinoid can be 
responsible for diffuse wheezing masquerading 
as asthma. Finally, inadequate medication may 
be the cause of failure to improve. Readings of 
serum theophylline at the level obtained one 
hour after a dose has been given, and one hour 
before the next dose, are helpful indications of 
whether an adequate amount has been given 
There is a tendency to underuse corticosteroids 
in severe acute respiratory failure . It is better to 
overuse the steroids for a short period than to 
have the patient suffer cardiac, respiratory or 
neurologic damage if complications arise. 
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INTRODUCTION 
The 32nd Stoneburner Lecture Series, 
''New Concepts in the Outpatient Management 
of Chronic Obstructive Pulmonary Disease and 
Asthma, " was presented on April 6 and 7, 
1979 , to an audience consisting principally of 
family practitioners and internists. The confer-
ence explored new concepts about COPD and 
asthma which have emerged from basic and 
clinical research during the last decade. In par-
ticular, practical management related to drug 
treatment , pulmonary rehabilitation , pulmonary 
function testing, pre- and postoperative care , 
and the use of oxygen were emphasized . 
James P. Baker, M. D., Chairman , De-
partment of Medicine, Eastern Virginia School 
of Medicine, and a former member of the Pul-
monary Division at the Medical College of Vir-
ginia, was the Stoneburner Lecturer. He re-
viewed and updated the modern outpatient 
management of chronic obstructive pulmonary 
disease. Raymond Casciari , M.D., Director of 
the Rehabilitation Center, St. Joseph's Hospital , 
Anaheim, California, and Clinical Instructor of 
Medicine at the University of California, Irvine, 
talked about his experience in establishing a 
pulmonary rehabilitation program in a commu-
nity hospital. In addition, Dr. Casciari stressed 
the physiological benefits derived from rehabili-
tation. 
The Medical College of Virginia Pulmo-
nary faculty and selected pulmonary fellows ac-
tively participated in the preparation of the lec-
tures. The audience 's response was excellent 
as evidenced by the many questions asked and 
the excellent post-program evaluation . 
The Pulmonary Division would like to 
thank the Department of Continuing Medical 
Education for planning this symposium . 
FREDERICK L. GLAUSER, M.D. 
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